Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
38.6 /100
Rank 16 out of 27 Sectors -
Advance/Decline
266/384
-
No. of Companies650
-
Avg. Market Cap8,463
-
Price to Earning Ratio7.26
-
Price to Earning Growth Ratio1.14
-
Price to Book Ratio27.37
-
Return on Equity5.82
-
Return on Capital Employed-
-
Return on Assets2.98
-
Dividend yield 1 year %0.64 %
-
Net Profit Growth Annual YoY %8.90 %
-
Net Profit Growth Qtr YoY %100.90 %
-
Net Profit Growth Qtr QoQ %186.84 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
368,857.7
|
208.5
|
L
 0.1%
H
206.5
209.7
|
L
 -1.4%
H
203.0
214.1
|
L
 -5.1%
H
201.7
224.4
|
L
 -3.0%
H
201.7
237.1
|
L
 18.0%
H
168.5
244.8
|
L
 29.1%
H
131.0
244.8
|
L
 95.1%
H
105.6
244.8
|
L
 250.4%
H
55.1
244.8
|
| Adc Therapeutics SA |
|
560.3
|
4.4
|
L
 0.9%
H
4.2
4.8
|
L
 18.2%
H
3.7
4.8
|
L
 6.8%
H
3.5
4.8
|
L
 24.2%
H
3.3
5.0
|
L
 264.5%
H
1.1
5.0
|
L
 102.3%
H
0.4
6.0
|
L
 -81.3%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
4,162.9
|
13.1
|
L
H
12.9
13.2
|
L
 2.7%
H
12.3
13.2
|
L
 10.3%
H
11.7
13.2
|
L
 -1.1%
H
11.7
15.4
|
L
 82.0%
H
7.0
15.4
|
L
 859.6%
H
1.4
15.4
|
L
 121.2%
H
1.2
15.4
|
L
 -62.9%
H
1.2
37.2
|
| Annovis Bio Inc |
|
51.8
|
1.8
|
L
 0.6%
H
1.7
1.8
|
L
 -23.0%
H
1.5
2.0
|
L
 -29.8%
H
1.5
3.0
|
L
 -44.7%
H
1.5
3.3
|
L
 45.1%
H
1.2
5.5
|
L
 -88.2%
H
1.1
22.5
|
L
 -91.8%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,162.4
|
5.8
|
L
 0.9%
H
5.7
5.9
|
L
 8.2%
H
5.2
5.9
|
L
 16.7%
H
4.9
5.9
|
L
 -20.3%
H
4.9
7.3
|
L
 28.1%
H
4.4
8.7
|
L
 -22.7%
H
4.0
11.5
|
L
 -80.9%
H
4.0
34.5
|
L
 -82.0%
H
4.0
38.5
|
| Bristol-Myers Squibb |
|
120,258.2
|
58.9
|
L
 1.7%
H
57.7
58.9
|
L
 -0.5%
H
57.2
59.8
|
L
 -0.3%
H
56.5
62.2
|
L
 4.0%
H
53.5
62.9
|
L
 17.8%
H
42.5
62.9
|
L
 -16.4%
H
39.4
70.9
|
L
 -8.6%
H
39.4
81.4
|
L
 -13.4%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
449.3
|
8.7
|
L
 0.5%
H
8.4
8.8
|
L
 3.7%
H
7.9
8.8
|
L
 7.8%
H
7.7
8.8
|
L
 -20.6%
H
7.7
12.6
|
L
 87.9%
H
4.4
14.1
|
L
 -26.6%
H
1.4
15.1
|
L
 -88.3%
H
1.4
77.8
|
L
 -76.7%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
11,450.8
|
22.9
|
L
 -1.3%
H
22.9
23.4
|
L
 -2.8%
H
22.6
24.4
|
L
 0.0%
H
22.1
25.7
|
L
 -5.2%
H
22.1
27.7
|
L
 178.3%
H
8.0
27.7
|
L
 147.1%
H
7.9
27.7
|
L
 -24.1%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
114,184.3
|
57.2
|
L
 -1.1%
H
57.1
57.8
|
L
 -0.4%
H
57.0
59.6
|
L
 7.1%
H
51.5
59.6
|
L
 16.4%
H
47.6
61.7
|
L
 60.2%
H
35.1
61.7
|
L
 51.4%
H
31.7
61.7
|
L
 49.0%
H
28.5
61.7
|
L
 31.0%
H
28.5
61.7
|
| Johnson & Johnson |
|
564,386.2
|
234.3
|
L
 -1.8%
H
232.1
238.1
|
L
 -2.9%
H
232.1
244.2
|
L
 -3.0%
H
232.1
247.2
|
L
 6.7%
H
210.5
251.7
|
L
 52.5%
H
146.1
251.7
|
L
 41.3%
H
140.7
251.7
|
L
 46.1%
H
140.7
251.7
|
L
 112.7%
H
109.2
251.7
|
| Eli Lilly |
|
808,023.9
|
904.5
|
L
 -0.1%
H
898.2
920
|
L
 -5.1%
H
888.0
963.9
|
L
 -8.2%
H
877.1
998.2
|
L
 -12.4%
H
877.1
1114
|
L
 19.5%
H
623.8
1134.0
|
L
 141.4%
H
367.4
1134.0
|
L
 386.5%
H
178.6
1134.0
|
L
 1097.5%
H
64.2
1134.0
|
| Merck & Company |
|
285,419.2
|
115.6
|
L
 -2.0%
H
114.7
117.9
|
L
 -6.2%
H
114.7
124
|
L
 0.7%
H
112.7
124
|
L
 4.1%
H
106.0
125.1
|
L
 47.4%
H
73.3
125.1
|
L
 0.2%
H
73.3
134.6
|
L
 58.0%
H
69.5
134.6
|
L
 115.7%
H
50.4
134.6
|
| Nuvation Bio Inc (Class A) |
|
1,682.8
|
4.8
|
L
 0.4%
H
4.6
4.9
|
L
 6.8%
H
4.4
4.9
|
L
 9.0%
H
4.0
4.9
|
L
 -21.2%
H
4.0
6.3
|
L
 139.6%
H
1.6
9.8
|
L
 168.9%
H
1.0
9.8
|
L
 -58.8%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
181,457.0
|
40.9
|
L
 0.2%
H
40.2
41.4
|
L
 8.8%
H
36.8
41.4
|
L
 7.7%
H
35.1
41.4
|
L
 -28.4%
H
35.1
64.2
|
L
 -36.6%
H
35.1
81.4
|
L
 -51.5%
H
35.1
148.2
|
L
 14.4%
H
35.1
148.2
|
L
 45.7%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
285,688.5
|
149.7
|
L
 -1.6%
H
149.4
150.9
|
L
 -3.0%
H
149.4
156.5
|
L
 -2.4%
H
145.3
156.5
|
L
 4.6%
H
142.8
170.5
|
L
 36.2%
H
104.9
170.5
|
L
 53.0%
H
92.2
170.5
|
L
 71.7%
H
74.1
170.5
|
L
 123.8%
H
59.2
170.5
|
| Organon & Co. |
|
2,420.9
|
9.3
|
L
 1.0%
H
9.2
9.8
|
L
 58.7%
H
5.8
9.8
|
L
 46.5%
H
5.7
9.8
|
L
 6.9%
H
5.7
9.9
|
L
 -15.8%
H
5.7
13.2
|
L
 -60.9%
H
5.7
24.8
|
L
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,699.1
|
57.0
|
L
 -0.9%
H
56.7
57.9
|
L
 2.7%
H
54.9
57.9
|
L
 -7.2%
H
51.2
64.5
|
L
 -13.1%
H
51.2
71.1
|
L
 -29.5%
H
51.2
89.4
|
L
 -9.2%
H
51.2
90.0
|
L
 26.7%
H
43.2
90.0
|
L
 1.0%
H
26.3
90.0
|
| Pfizer |
|
154,893.9
|
27.2
|
L
 0.2%
H
27.2
27.5
|
L
 -0.9%
H
26.7
27.6
|
L
 2.5%
H
26.4
28.7
|
L
 5.2%
H
25.1
28.7
|
L
 21.4%
H
21.9
28.7
|
L
 -33.9%
H
20.9
41.3
|
L
 -27.6%
H
20.9
61.7
|
L
 -11.6%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,581.6
|
11.5
|
L
 0.7%
H
11.3
11.6
|
L
 6.1%
H
10.4
11.6
|
L
 23.6%
H
9.2
11.6
|
L
 -24.3%
H
9.2
15.4
|
L
 -54.2%
H
9.2
28.4
|
L
 -68.5%
H
9.2
40.3
|
L
 -72.1%
H
9.2
50.9
|
L
 -91.0%
H
9.2
132.2
|
| Arcus Biosciences Inc |
|
2,923.1
|
23.3
|
L
 -1.6%
H
23.0
23.7
|
L
 3.0%
H
22.1
23.9
|
L
 6.1%
H
20
23.9
|
L
 7.0%
H
18.5
24.9
|
L
 191.1%
H
7.1
26.4
|
L
 33.0%
H
6.5
26.4
|
L
 -33.4%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
10,873.7
|
13.1
|
L
 0.9%
H
13.0
13.1
|
L
 -1.4%
H
12.9
13.6
|
L
 -7.6%
H
12.8
14.3
|
L
 -0.2%
H
12.8
14.8
|
L
 -2.0%
H
12.8
16.2
|
L
 8.7%
H
10.6
74.9
|
L
 1.8%
H
9.6
74.9
|
L
 41.0%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
56,265.2
|
17.8
|
L
 -0.2%
H
17.7
17.9
|
L
 -4.6%
H
17.6
18.6
|
L
 0.2%
H
17.6
18.9
|
L
 9.1%
H
15.8
18.9
|
L
 22.5%
H
13.0
18.9
|
L
 5.9%
H
12.6
18.9
|
L
 3.5%
H
12.3
18.9
|
L
 -28.6%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
36,445.8
|
31.3
|
L
 -1.0%
H
31.2
31.8
|
L
 2.6%
H
30.2
32.0
|
L
 9.6%
H
27.9
32.0
|
L
 -3.3%
H
27.9
37.3
|
L
 130.2%
H
13.0
37.3
|
L
 277.6%
H
7.1
37.3
|
L
 189.0%
H
6.8
37.3
|
L
 -43.3%
H
6.1
58.2
|
| Usana Health Sciences Inc |
|
351.4
|
19.0
|
L
 0.7%
H
18.4
19.0
|
L
 5.4%
H
17.6
19.0
|
L
 9.8%
H
16.6
19.0
|
L
 -11.9%
H
16.6
22.9
|
L
 -20.7%
H
16.6
38.3
|
L
 -70.4%
H
16.6
69.6
|
L
 -81.2%
H
16.6
107.9
|
L
 -69.0%
H
16.6
138.0
|
| Zoetis (Class A) |
|
50,188.7
|
119.4
|
L
 -1.2%
H
119.1
122.0
|
L
 -0.3%
H
116.9
122.5
|
L
 3.2%
H
113.3
122.5
|
L
 -4.7%
H
113.3
132.5
|
L
 -20.0%
H
113.3
172.2
|
L
 -31.6%
H
113.3
201.9
|
L
 -27.9%
H
113.3
249.3
|
L
 148.1%
H
45.3
249.3
|
| Biohaven Ltd |
|
1,505.7
|
10.0
|
L
 -3.5%
H
10.0
10.6
|
L
 6.7%
H
9.0
10.8
|
L
 4.5%
H
8.0
10.8
|
L
 -16.0%
H
8.0
14.0
|
L
 -46.1%
H
7.5
24.1
|
L
 -23.5%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Whitehawk Therapeutics Inc |
|
198.7
|
4.2
|
L
 8.0%
H
3.9
4.4
|
L
 23.5%
H
3.3
4.4
|
L
 7.7%
H
3.2
4.4
|
L
 50.9%
H
2.6
4.5
|
L
 150.6%
H
1.4
4.5
|
L
 -48.0%
H
1.2
8.7
|
L
 -76.6%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,155.0
|
3.8
|
L
 -1.3%
H
3.8
4.0
|
L
 11.1%
H
3.4
4.0
|
L
 9.2%
H
3.2
4.0
|
L
 -8.9%
H
2.7
4.9
|
L
 56.8%
H
1.9
6.5
|
L
 -48.4%
H
1.9
8.1
|
L
 -86.9%
H
1.9
36.1
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
305.2
|
5.4
|
L
 -0.9%
H
5.3
5.4
|
L
 9.9%
H
4.8
5.5
|
L
 12.4%
H
4.2
5.5
|
L
 -1.8%
H
4.2
5.7
|
L
 8.7%
H
4
7.5
|
L
 91.8%
H
2.8
9.0
|
L
 -85.7%
H
2.2
51
|
L
 -92.3%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
3,311.9
|
66.9
|
L
 2.0%
H
63.9
67.9
|
L
 7.8%
H
59
67.9
|
L
 67.1%
H
37.6
67.9
|
L
 105.7%
H
31
67.9
|
L
 681.0%
H
8.3
67.9
|
L
 178.3%
H
2.2
67.9
|
L
 63.8%
H
2.2
67.9
|
L
 -91.7%
H
2.2
939.6
|
| Acumen Pharma Inc |
|
194.3
|
2.7
|
L
 -1.1%
H
2.7
2.7
|
L
 4.3%
H
2.5
2.7
|
L
 -17.7%
H
2.2
3.6
|
L
 44.6%
H
1.8
3.6
|
L
 156.2%
H
0.9
3.6
|
L
 -28.1%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
925.6
|
4.7
|
L
 4.9%
H
4.4
4.7
|
L
 7.3%
H
4.1
4.8
|
L
 10.3%
H
4.1
4.8
|
L
H
3.5
4.9
|
L
 48.7%
H
2.9
5.1
|
L
 63.8%
H
1.7
5.1
|
L
 46.9%
H
1.7
6.5
|
L
 -3.1%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
31.8
|
1.2
|
L
 -5.3%
H
1.2
1.4
|
L
 -12.7%
H
1.2
1.6
|
L
 -2.4%
H
0.9
1.8
|
L
 -39.5%
H
0.9
2.2
|
L
 37.8%
H
0.8
5.5
|
L
 -79.9%
H
0.4
9.6
|
L
 -97.2%
H
0.4
299.5
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
3,616.2
|
21.2
|
L
 -2.5%
H
21.2
22.1
|
L
 -6.0%
H
21.0
22.7
|
L
 2.9%
H
19.9
22.9
|
L
 -20.1%
H
19.9
27.8
|
L
 41.5%
H
14.1
28.4
|
L
 17.9%
H
13.4
33.9
|
L
 0.0%
H
12.2
33.9
|
L
 -36.7%
H
12.2
58.7
|
| Adicet Bio Inc |
|
76.0
|
7.9
|
L
H
7.7
8.2
|
L
 20.9%
H
6.1
8.2
|
L
 9.9%
H
6.0
8.2
|
L
 -0.3%
H
6.0
9
|
L
 -16.4%
H
6.0
17.4
|
L
 -91.2%
H
6.0
120
|
L
 -96.2%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
260.3
|
4.9
|
L
 37.8%
H
4.0
5.3
|
L
 50%
H
3.1
5.3
|
L
 17.3%
H
2.6
5.3
|
L
 -12.5%
H
2.6
6.0
|
L
 126.4%
H
2.0
6.0
|
L
 -32.6%
H
1.8
10.3
|
L
 -52.2%
H
1.8
11.8
|
L
 -99.7%
H
1.8
3123.8
|
| AC Immune SA |
|
314.5
|
3.1
|
L
 -1.6%
H
2.9
3.2
|
L
 -3.7%
H
2.9
3.5
|
L
 2.3%
H
2.6
3.5
|
L
 -14.9%
H
2.4
3.9
|
L
 104.6%
H
1.5
4
|
L
 37.9%
H
1.4
5.1
|
L
 -56.2%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Arcellx Inc |
|
6,726.9
|
115.0
|
L
 0.0%
H
115
115.1
|
L
 0.2%
H
114.8
115.1
|
L
 0.6%
H
114.3
115.1
|
L
 68.4%
H
63.1
115.1
|
L
 87.3%
H
47.9
115.1
|
L
 270.9%
H
30.7
115.1
|
L
H
6.0
115.1
|
L
H
6.0
115.1
|
| Aclaris Therapeutics Inc |
|
480.7
|
4.0
|
L
 1.0%
H
3.9
4.0
|
L
 0.5%
H
3.8
4.2
|
L
 12.2%
H
3.2
4.2
|
L
 48.7%
H
2.6
4.9
|
L
 254.5%
H
1.1
4.9
|
L
 -55.1%
H
0.6
11.1
|
L
 -85.3%
H
0.6
28.3
|
L
 -80.2%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
65.1
|
1.7
|
L
 0.6%
H
1.7
1.7
|
L
 9.8%
H
1.4
1.7
|
L
 3.7%
H
1.3
1.8
|
L
 -10.2%
H
1.3
2.2
|
L
 -21.9%
H
1.1
3.6
|
L
 -80.0%
H
1.1
14.3
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
14.1
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 5.1%
H
0.7
0.9
|
L
 3.8%
H
0.7
0.9
|
L
 -16.2%
H
0.7
1.0
|
L
 66%
H
0.4
1.6
|
L
 20.3%
H
0.4
1.6
|
L
 -96.8%
H
0.4
33.4
|
L
 -98.9%
H
0.4
115
|
| Grace Therapeutics Inc |
|
68.4
|
4.4
|
L
 1.4%
H
4.1
4.6
|
L
 23.8%
H
3.4
4.8
|
L
 5.2%
H
2.5
5.2
|
L
 21.4%
H
2.5
5.2
|
L
 104.6%
H
2.0
5.2
|
L
 56.7%
H
1.7
5.2
|
L
 -79.0%
H
1.7
32.6
|
L
 -93.2%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
7.2
|
2.5
|
L
 -18.7%
H
2.2
2.7
|
L
 -14.9%
H
2.2
3.2
|
L
 -35.1%
H
2.2
7.5
|
L
 -6.3%
H
1.3
7.5
|
L
 -66.8%
H
1.3
21
|
L
 -95.7%
H
1.3
176.4
|
L
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
2.3
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 -2.4%
H
1.5
1.7
|
L
 -17.9%
H
1.5
2.1
|
L
 -71.7%
H
1.5
6.1
|
L
 -91.2%
H
1.5
30.3
|
L
 -99.1%
H
1.5
350
|
L
 -99.9%
H
1.5
3175
|
L
H
1.5
5900
|
| Adma Biologics Inc |
|
2,562.6
|
10.8
|
L
 1.0%
H
10.4
10.9
|
L
 9.5%
H
9.6
10.9
|
L
 -29.0%
H
7.2
16.4
|
L
 -38.5%
H
7.2
18
|
L
 -51.4%
H
7.2
25.7
|
L
 238.4%
H
3.1
25.7
|
L
 522.0%
H
1.0
25.7
|
L
 44.6%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,174.2
|
14.1
|
L
 -2.8%
H
14.0
14.5
|
L
 -4.9%
H
12.4
14.9
|
L
 7.2%
H
12.0
15.6
|
L
 -20.6%
H
12
19.8
|
L
 82.4%
H
6.8
20.8
|
L
 78.5%
H
2.3
20.8
|
L
 -67.2%
H
2.3
45.0
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.4
|
0.4
|
L
 -6.7%
H
0.4
0.5
|
L
 -19.2%
H
0.4
0.5
|
L
 -76.9%
H
0.4
1.8
|
L
 -92.9%
H
0.4
14.7
|
L
 -100.0%
H
0.4
2594.5
|
L
 -100.0%
H
0.4
10000000000
|
L
 -100.0%
H
0.4
10000000000
|
L
H
0.4
10000000000
|
| Agenus Inc |
|
177.8
|
4.6
|
L
 -4.1%
H
4.6
4.8
|
L
 10.2%
H
3.9
5.1
|
L
 49.4%
H
2.9
5.1
|
L
 25.8%
H
2.7
5.1
|
L
 174.0%
H
1.6
7.3
|
L
 -83.7%
H
1.4
196
|
L
 -91.1%
H
1.4
196
|
L
 -94.5%
H
1.4
196
|
| Agios Pharma Inc |
|
2,041.4
|
34.8
|
L
 1.1%
H
34.3
35.0
|
L
 3.2%
H
32.5
35.0
|
L
 25.1%
H
27.4
36.4
|
L
 25.3%
H
26.0
36.4
|
L
 25.2%
H
22.2
46
|
L
 58.8%
H
19.8
62.6
|
L
 -36.7%
H
16.8
62.6
|
L
 -28.3%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
279.3
|
69.0
|
L
 7.8%
H
64.6
69.5
|
L
 32.7%
H
50.9
75
|
L
 73.0%
H
40.7
75
|
L
 108.5%
H
30.9
75
|
L
 354.5%
H
13.9
75
|
L
 1739.7%
H
2.7
75
|
L
 -65.3%
H
2.7
217
|
L
 -72.3%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
364.3
|
1.4
|
L
 -12.3%
H
1.4
1.6
|
L
 -4.9%
H
1.4
1.6
|
L
 -6.9%
H
1.3
1.6
|
L
 1.5%
H
1.1
1.6
|
L
 -28.0%
H
1.1
4.1
|
L
 115.9%
H
0.6
4.1
|
L
 -55.6%
H
0.2
4.3
|
L
 -86.3%
H
0.2
20.3
|
| Avalon GloboCare Corp |
|
3.3
|
0.4
|
L
H
0.3
0.4
|
L
 -24.5%
H
0.3
0.6
|
L
 -42.0%
H
0.3
0.7
|
L
 -64.9%
H
0.3
1.6
|
L
 -89.7%
H
0.3
5.2
|
L
 -80.3%
H
0.2
11.7
|
L
 -96.1%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
107.1
|
1.8
|
L
 -2.7%
H
1.7
1.8
|
L
 13.4%
H
1.5
1.9
|
L
 -56.8%
H
1.1
4.5
|
L
 -59.6%
H
1.1
5.9
|
L
 -19.1%
H
1.1
6.2
|
L
 -83.0%
H
1.1
12.0
|
L
 -84.6%
H
1.1
16.0
|
L
 -68.2%
H
1.1
16.7
|
| Alector Inc |
|
282.5
|
2.6
|
L
 -0.8%
H
2.5
2.7
|
L
 5.8%
H
2.3
2.7
|
L
 16.4%
H
2.0
2.7
|
L
 40.7%
H
1.7
2.7
|
L
 137.0%
H
0.9
3.4
|
L
 -60.4%
H
0.9
9.1
|
L
 -86.1%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
46.1
|
7.5
|
L
 0.4%
H
7.3
8.7
|
L
 -6.8%
H
7.2
9.0
|
L
 -1.6%
H
6.4
9.0
|
L
 -9.8%
H
6.2
9.0
|
L
 57.8%
H
4.2
13.7
|
L
 -68.0%
H
3.8
46.3
|
L
 -98.7%
H
3.8
857.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
5,650.9
|
34.0
|
L
 2.3%
H
33.1
34
|
L
 -2.2%
H
32.8
35.5
|
L
 22.4%
H
27
36.5
|
L
 8.9%
H
27
36.5
|
L
 21.7%
H
25.2
36.5
|
L
 15.8%
H
22.0
36.5
|
L
 71.9%
H
19.6
36.5
|
L
 -14.2%
H
12.0
71.2
|
| Allogene Therapeutics Inc |
|
572.9
|
2.4
|
L
 8.3%
H
2.2
2.5
|
L
 -13.0%
H
1.9
4.5
|
L
 -2.1%
H
1.9
4.5
|
L
 46.0%
H
1.5
4.5
|
L
 61.0%
H
0.9
4.5
|
L
 -52.9%
H
0.9
6.9
|
L
 -92.8%
H
0.9
35.9
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
19.5
|
1.2
|
L
 -1.6%
H
1.2
1.2
|
L
 6.0%
H
1.1
1.3
|
L
 -2.4%
H
1.0
1.3
|
L
 4.2%
H
0.8
1.4
|
L
 46.4%
H
0.8
2.1
|
L
 -99.9%
H
0.1
2520
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
42,793.0
|
320.7
|
L
 -3.8%
H
320.0
333.4
|
L
 -2%
H
317.5
343.4
|
L
 2.3%
H
299.6
343.4
|
L
 -10.7%
H
298
376.9
|
L
 38.9%
H
225.8
495.6
|
L
 57.3%
H
142.0
495.6
|
L
 130.7%
H
117.6
495.6
|
L
 366.2%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
47.9
|
1.7
|
L
 -3.9%
H
1.7
1.9
|
L
 8.9%
H
1.4
1.9
|
L
 31.5%
H
1.1
1.9
|
L
 47.4%
H
1.1
1.9
|
L
 -0.6%
H
1.0
2.4
|
L
 3.6%
H
1.0
7.4
|
L
 -92.8%
H
1.0
28
|
L
H
1.0
309.6
|
| Altimmune Inc |
|
459.3
|
3.5
|
L
 3.8%
H
3.4
3.6
|
L
 4.8%
H
3.2
3.6
|
L
 0.9%
H
2.9
3.7
|
L
 -16.8%
H
2.9
6.4
|
L
 -22.1%
H
2.9
7.7
|
L
 -26.2%
H
2.1
14.8
|
L
 -72.3%
H
2.1
23.5
|
L
 -99.5%
H
1.5
1050
|
| Alvotech |
|
1,132.7
|
3.6
|
L
 -0.8%
H
3.6
3.7
|
L
 1.4%
H
3.4
3.8
|
L
 4.6%
H
3.0
3.9
|
L
 -26.7%
H
3.0
5.6
|
L
 -57.8%
H
3.0
11.9
|
L
 -65.9%
H
3.0
18
|
L
H
3.0
18
|
L
H
3.0
18
|
| Kalaris Therapeutics Inc |
|
149.3
|
6.5
|
L
 10.9%
H
6
6.7
|
L
 2.7%
H
5.4
6.7
|
L
 -24.9%
H
5.2
9.3
|
L
 -26.5%
H
5.2
11.2
|
L
 0.8%
H
2.1
11.9
|
L
 67.8%
H
0.4
12.9
|
L
 -71.2%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alzamend Neuro Inc |
|
3.8
|
1.0
|
L
 -2.9%
H
1.0
1.0
|
L
 6.5%
H
0.8
1.1
|
L
 -51.5%
H
0.8
2.4
|
L
 -56%
H
0.8
2.5
|
L
 -85.5%
H
0.8
8.2
|
L
 -99.9%
H
0.8
1071.9
|
L
H
0.8
45292.5
|
L
H
0.8
45292.5
|
| Amgen |
|
187,902.8
|
348.6
|
L
 0.1%
H
346.6
351.3
|
L
 -0.4%
H
344.2
359.4
|
L
 -4.8%
H
335.1
370.9
|
L
 5.6%
H
321.7
391.3
|
L
 18.0%
H
261.4
391.3
|
L
 39.4%
H
211.7
391.3
|
L
 36.6%
H
198.6
391.3
|
L
 117.7%
H
133.6
391.3
|
| Amylyx Pharma Inc |
|
1,948.8
|
17.6
|
L
 3.0%
H
16.8
17.8
|
L
 4.2%
H
16.1
17.8
|
L
 26.0%
H
12.7
17.8
|
L
 30.4%
H
12.7
17.8
|
L
 354.4%
H
3.8
17.8
|
L
 -41.2%
H
1.6
31.8
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
976.2
|
21.9
|
L
 1.1%
H
21.4
22.0
|
L
 7.5%
H
20.1
22.0
|
L
 20.6%
H
18.7
22.0
|
L
 -15.7%
H
17.0
29.5
|
L
 -6.7%
H
17.0
31.3
|
L
 -48.0%
H
17.0
67.7
|
L
 26.3%
H
17.0
67.7
|
L
 72.3%
H
11.4
67.7
|
| AnaptysBio Inc |
|
1,929.3
|
67.1
|
L
 -1.2%
H
65.8
68.3
|
L
 2.4%
H
64.6
73.3
|
L
 3.6%
H
54.2
73.3
|
L
 44.9%
H
44.3
73.3
|
L
 270.8%
H
17.1
73.3
|
L
 211.7%
H
12.2
73.3
|
L
 204.1%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,775.0
|
78.0
|
L
 2.0%
H
76.5
78.3
|
L
 -1.3%
H
75.9
80.8
|
L
 10.7%
H
70.4
82.1
|
L
 -8.5%
H
70.2
87.1
|
L
 12.2%
H
56.7
99.5
|
L
 103.1%
H
37.0
99.5
|
L
 124.5%
H
22.3
99.5
|
L
 80.4%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
94.5
|
2.8
|
L
 -3.8%
H
2.8
2.9
|
L
 3.3%
H
2.6
2.9
|
L
 -0.4%
H
2.4
2.9
|
L
 -12.4%
H
2.4
3.4
|
L
 -1.1%
H
2.4
5.5
|
L
 -52.8%
H
2.1
6.5
|
L
 -42.7%
H
2.1
6.5
|
L
 2.9%
H
0.6
8.1
|
| Annexon Inc |
|
1,020.6
|
6.4
|
L
 0.2%
H
6.1
6.4
|
L
 5.1%
H
5.7
6.4
|
L
 12.4%
H
4.9
6.4
|
L
 3.3%
H
4.8
7.2
|
L
 313.0%
H
1.4
7.2
|
L
 31.4%
H
1.3
8.4
|
L
 -73.4%
H
1.3
24.9
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
113.2
|
3.2
|
L
 -3.4%
H
3.0
3.3
|
L
 -5.7%
H
2.9
3.4
|
L
 -36.2%
H
2.9
5.2
|
L
 152%
H
1
6.9
|
L
 150%
H
1
6.9
|
L
 -64.1%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
3.3
|
0.6
|
L
 -4.9%
H
0.5
0.7
|
L
 -6.5%
H
0.5
0.8
|
L
 -23.7%
H
0.5
0.9
|
L
 -64.4%
H
0.5
1.7
|
L
 -95.4%
H
0.5
14.2
|
L
 -100.0%
H
0.5
27900
|
L
 -100.0%
H
0.5
121500
|
L
 -100.0%
H
0.5
2167200
|
| Apollomics Inc (Class A) |
|
30.6
|
14.3
|
L
H
14.3
14.5
|
L
 -7.3%
H
13
16.0
|
L
 -28.3%
H
13
20.1
|
L
 -29.2%
H
13
22
|
L
 157.1%
H
3.7
42.1
|
L
 -97.6%
H
0.1
662
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
5,224.9
|
40.9
|
L
 0.1%
H
40.8
40.9
|
L
 0.4%
H
40.6
40.9
|
L
 115.8%
H
16.8
40.9
|
L
 99.1%
H
16.8
40.9
|
L
 115.5%
H
16.1
40.9
|
L
 -49.5%
H
16.1
94.8
|
L
 -8.7%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Aptorum Grp Ltd (Class A) |
|
7.4
|
0.9
|
L
 -4.2%
H
0.9
0.9
|
L
 5.8%
H
0.8
1.0
|
L
 15.2%
H
0.8
1.3
|
L
 -13.3%
H
0.7
1.3
|
L
 -15.7%
H
0.7
4.5
|
L
 -64.3%
H
0.5
17.5
|
L
 -96.4%
H
0.5
35.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
10.5
|
0.9
|
L
 -2.1%
H
0.9
1.0
|
L
 31.4%
H
0.7
1.0
|
L
 24.3%
H
0.6
1.0
|
L
 3.4%
H
0.6
1.5
|
L
 -41.8%
H
0.6
2.2
|
L
 -77.6%
H
0.6
8.9
|
L
 -98.9%
H
0.6
156
|
L
H
0.6
1062.2
|
| Aptevo Therapeutics Inc |
|
6.5
|
5.5
|
L
 2.4%
H
5.3
5.6
|
L
 29.0%
H
4.2
5.6
|
L
 24.9%
H
3.8
5.6
|
L
 -38.9%
H
3.8
10.7
|
L
 -98.4%
H
3.8
486
|
L
 -100.0%
H
3.8
1224907.2
|
L
 -100.0%
H
3.8
18613900.8
|
L
H
3.8
68020444.8
|
| AquaBounty Tech Inc |
|
5.0
|
1.0
|
L
 -12.5%
H
1.0
1.1
|
L
 5.4%
H
0.9
1.2
|
L
 4.3%
H
0.9
1.2
|
L
H
0.8
1.2
|
L
 42.0%
H
0.6
3.0
|
L
 -91.5%
H
0.5
11.9
|
L
 -99.2%
H
0.5
130.6
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
522.4
|
4.3
|
L
 0.9%
H
4.2
4.3
|
L
 2.4%
H
4.0
4.3
|
L
 6.5%
H
3.8
4.3
|
L
 28.1%
H
2.9
4.5
|
L
 66.5%
H
2.1
7.6
|
L
 237.0%
H
1.2
7.6
|
L
 -1.4%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
250.1
|
8.8
|
L
 2.1%
H
8.4
8.9
|
L
 3.5%
H
8.1
8.9
|
L
 31.7%
H
6.4
9.1
|
L
 15.6%
H
6.4
9.1
|
L
 -16.8%
H
5.9
24.2
|
L
 -68.1%
H
5.9
45
|
L
 -77.7%
H
5.9
65
|
L
 -71.4%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,540.2
|
6.3
|
L
 -0.3%
H
6.2
6.4
|
L
 3.0%
H
6.0
6.5
|
L
 8.7%
H
5.1
6.5
|
L
 -10.8%
H
5.1
8.4
|
L
 35.3%
H
3.2
8.4
|
L
 33.3%
H
3.2
10.1
|
L
 -27.5%
H
0.5
10.1
|
L
 -23.7%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
2,983.0
|
24.1
|
L
 -2.2%
H
23.7
24.6
|
L
 -2.3%
H
23.6
25.5
|
L
 5.7%
H
21.1
25.5
|
L
 -8.8%
H
21.1
28.8
|
L
 82.3%
H
12.4
31.8
|
L
 73.1%
H
1.8
31.8
|
L
 -16.1%
H
1.8
36.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
3.8
|
4.7
|
L
 -12.2%
H
4.2
5.2
|
L
 -31.9%
H
4.2
6.9
|
L
 23.9%
H
3.0
19.9
|
L
 -6.4%
H
3.0
19.9
|
L
 -74.9%
H
3.0
85.8
|
L
 -90.1%
H
3.0
85.8
|
L
 -98.5%
H
3.0
388.8
|
L
H
3.0
46656
|
| Arvinas Inc |
|
695.9
|
10.9
|
L
 -0.8%
H
10.7
11.1
|
L
 -2.9%
H
10.6
11.5
|
L
 -10.7%
H
10.0
12.5
|
L
 -10.3%
H
10.0
14.5
|
L
 43.5%
H
5.9
14.5
|
L
 -59.5%
H
5.9
53.1
|
L
 -82.7%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
9,473.2
|
67.7
|
L
 -4.7%
H
67.4
72.2
|
L
 5.1%
H
63.3
72.2
|
L
 22.9%
H
54.9
72.2
|
L
 2.1%
H
54.0
76.1
|
L
 425.6%
H
10.9
76.8
|
L
 122.1%
H
9.6
76.8
|
L
 -0.5%
H
9.6
93.7
|
L
 985.9%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
467.9
|
29.5
|
L
 -1.0%
H
29.1
30.1
|
L
 0.5%
H
28.3
30.7
|
L
 4.9%
H
26.3
30.7
|
L
 -1.4%
H
24.7
30.7
|
L
 200.7%
H
9.7
39.7
|
L
 148.3%
H
7.7
39.7
|
L
 -43.2%
H
7.7
56.3
|
L
 -52.6%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
639.6
|
5.1
|
L
 -5.6%
H
5.1
5.5
|
L
 12.9%
H
4.2
5.8
|
L
 -3.8%
H
3.9
5.8
|
L
 -32.1%
H
3.9
8.6
|
L
 -11.2%
H
3.9
14.5
|
L
 535%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
116.4
|
18.0
|
L
 0.1%
H
18.0
18.1
|
L
 -2.1%
H
18.0
18.2
|
L
 56.2%
H
11.3
20.5
|
L
 62.0%
H
10.7
20.5
|
L
 91%
H
8.6
20.5
|
L
 -80.9%
H
7.7
120.2
|
L
 -43.4%
H
7.7
120.2
|
L
 -98.1%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,491.8
|
4.1
|
L
 2.3%
H
3.9
4.5
|
L
 8.8%
H
3.6
4.5
|
L
 10.8%
H
3.3
4.5
|
L
 10.2%
H
3.3
4.5
|
L
 194.2%
H
1.3
6.8
|
L
 117.6%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| LeonaBio Inc |
|
78.9
|
8.4
|
L
 -11.4%
H
8.4
9.6
|
L
 -12.3%
H
8.4
10.7
|
L
 9.7%
H
6.9
14.2
|
L
 32.5%
H
4.2
14.2
|
L
 254.4%
H
2.2
14.2
|
L
 -67.3%
H
2.2
43.0
|
L
 -94.9%
H
2.2
236.4
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
47.7
|
2.4
|
L
 10.3%
H
2.1
2.4
|
L
 15.2%
H
1.8
2.4
|
L
 -18.7%
H
1.8
3.2
|
L
 -56.6%
H
1.8
5.7
|
L
 -73.6%
H
1.8
174.6
|
L
 -99.0%
H
1.8
279.3
|
L
 -100.0%
H
1.8
44650
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
49.5
|
5.8
|
L
 0.2%
H
5.5
5.8
|
L
 19.3%
H
4.7
5.8
|
L
 14.8%
H
4.6
6.1
|
L
 -33.9%
H
3.8
11.0
|
L
 -38.4%
H
3.8
19.4
|
L
 -48.2%
H
3.8
34.7
|
L
 -77.8%
H
3.8
147
|
L
 -99.2%
H
3.8
1107
|
| Atara Biotherapeutics Inc |
|
42.9
|
5.3
|
L
 0.2%
H
5.2
5.4
|
L
 4.8%
H
4.4
5.4
|
L
 -19.2%
H
4.3
6.5
|
L
 13.6%
H
3.9
7.3
|
L
 -12.2%
H
3.9
19.1
|
L
 -92.2%
H
0.4
77
|
L
 -98.5%
H
0.4
501
|
L
 -99.0%
H
0.4
1361.3
|
| Aurinia Pharma Inc |
|
2,107.6
|
15.9
|
L
 -1.3%
H
15.7
16.0
|
L
 -0.3%
H
15.6
16.5
|
L
 13.6%
H
13.8
16.5
|
L
 6.6%
H
13.5
16.5
|
L
 104.5%
H
7.3
16.5
|
L
 41.3%
H
4.7
16.5
|
L
 25.8%
H
4.1
34.0
|
L
 439.1%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
449.7
|
7.0
|
L
 -1.1%
H
6.9
7.0
|
L
 3.6%
H
6.6
7.2
|
L
 18.0%
H
5.9
7.2
|
L
 37.2%
H
4.7
7.2
|
L
 25.9%
H
4.3
7.5
|
L
 -19.4%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
450.9
|
5.7
|
L
 -3.7%
H
5.6
5.9
|
L
 -4.6%
H
5.6
6.0
|
L
 -7.2%
H
5.0
6.3
|
L
 64.5%
H
3.3
6.5
|
L
 100.7%
H
2.5
6.5
|
L
 72.6%
H
2.5
6.5
|
L
 -87.7%
H
2.5
47.0
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
556.7
|
29.7
|
L
 -0.1%
H
29
29.9
|
L
 -1.4%
H
28.9
31.5
|
L
 -11.0%
H
28.2
34.5
|
L
 52.0%
H
16.8
36.0
|
L
 65.3%
H
14.4
36.0
|
L
 161.9%
H
1.4
61.1
|
L
 -78.5%
H
1.4
144.1
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,067.2
|
21.6
|
L
 12.4%
H
18.9
21.8
|
L
 29.1%
H
16.3
21.8
|
L
 55.5%
H
12.9
21.8
|
L
 47.2%
H
12.9
21.8
|
L
 -77.0%
H
6.6
100.1
|
L
 -96.3%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
328.6
|
14.4
|
L
 8.0%
H
13.4
14.6
|
L
 0.1%
H
13.2
14.8
|
L
 -8.7%
H
13.1
18.5
|
L
 -7.8%
H
13.0
19.1
|
L
 194.3%
H
3.4
20.7
|
L
 454.6%
H
0.0
34.5
|
L
 -53.8%
H
0.0
44.4
|
L
 -67.1%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
315.1
|
3.4
|
L
 4.9%
H
3.2
3.4
|
L
 11.8%
H
2.9
3.4
|
L
 -26.9%
H
2.6
4.8
|
L
 -29.9%
H
2.6
5.4
|
L
 -62.7%
H
2.6
14.0
|
L
 -56.9%
H
2.6
14.4
|
L
 -71.9%
H
2.6
31.5
|
L
 -39.0%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
9,392.8
|
183.6
|
L
 -0.3%
H
180.2
185.0
|
L
 6.0%
H
172.0
185.1
|
L
 17.6%
H
152.3
185.1
|
L
 5.4%
H
152.3
191.5
|
L
 76.9%
H
96.1
191.5
|
L
 168.1%
H
55.0
191.5
|
L
 249.1%
H
19.4
191.5
|
L
 1766.1%
H
1.9
191.5
|
| Aytu BioPharma Inc |
|
27.5
|
2.6
|
L
 -1.2%
H
2.5
2.6
|
L
 -3.8%
H
2.5
2.7
|
L
 0.8%
H
2.5
2.8
|
L
 -7.3%
H
2.1
2.9
|
L
 146.2%
H
1.0
3.1
|
L
 0.4%
H
1.0
3.5
|
L
 -98.1%
H
1.0
144
|
L
 -100.0%
H
1.0
566400
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1.2
|
L
 2.6%
H
1.1
1.2
|
L
 2.6%
H
1.1
1.2
|
L
 8.3%
H
1.0
1.2
|
L
 42.7%
H
0.7
1.4
|
L
 -32.0%
H
0.5
2.6
|
L
 -18.8%
H
0.5
2.8
|
L
 -91.0%
H
0.5
13.3
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
253.1
|
3.8
|
L
 0.3%
H
3.7
3.9
|
L
 -4.3%
H
3.5
4.1
|
L
 -7.3%
H
3.4
4.8
|
L
 99.5%
H
1.7
4.8
|
L
 139.4%
H
1.3
4.8
|
L
 157.0%
H
1.1
4.8
|
L
 -71.0%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
8.6
|
7
|
L
H
7
7.5
|
L
 8.0%
H
6.5
7.6
|
L
 1.7%
H
5.4
7.6
|
L
 -13.6%
H
5.4
8.7
|
L
 -5.8%
H
5.4
12.1
|
L
 -54.9%
H
5
27.9
|
L
 -96.6%
H
5
229.6
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
5.9
|
5.1
|
L
 11.3%
H
4.6
5.1
|
L
 32.2%
H
3.8
5.1
|
L
 -44%
H
3.3
9.5
|
L
 -52.0%
H
3.3
11.6
|
L
 -89.3%
H
3.3
63.2
|
L
 -96.8%
H
3.3
219.8
|
L
 -99.7%
H
3.3
2192
|
L
 -100.0%
H
3.3
17759.8
|
| Amarin Corp (ADR) |
|
308.5
|
14.7
|
L
 -3.2%
H
14.4
15.2
|
L
 -0.1%
H
14.0
15.2
|
L
 -4.1%
H
13.8
15.8
|
L
 -1.3%
H
13.5
17.3
|
L
 50.0%
H
8.8
20.9
|
L
 989.6%
H
0.4
20.9
|
L
 193.6%
H
0.4
20.9
|
L
 750.3%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
51,454.8
|
827.4
|
L
 -1.6%
H
825.5
843.1
|
L
 5.4%
H
777.7
849.6
|
L
 18.1%
H
661.9
849.6
|
L
 1.7%
H
661.9
881.9
|
L
 36.7%
H
510.1
934.6
|
L
 116.0%
H
327.7
934.6
|
L
 198.2%
H
248.2
934.6
|
L
H
17.3
934.6
|
| Ascendis Pharma A/S (ADR) |
|
14,889.7
|
242.5
|
L
 0.3%
H
236.5
242.6
|
L
 4%
H
232.3
250.7
|
L
 7.3%
H
212.6
250.7
|
L
 12.8%
H
200.7
250.7
|
L
 57.6%
H
150.9
250.7
|
L
 198.8%
H
66.0
250.7
|
L
 95.3%
H
61.6
250.7
|
L
 1282.7%
H
11.9
250.7
|
| Alterity Therapeutics Ltd (ADR) |
|
69.8
|
3.9
|
L
 3.2%
H
3.7
3.9
|
L
 -1.3%
H
3.5
3.9
|
L
 6.9%
H
3.1
3.9
|
L
 16.3%
H
3.0
3.9
|
L
 16.7%
H
2.7
7
|
L
 33.7%
H
1
7
|
L
 -69.7%
H
1
27.5
|
L
 -89.3%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
423.2
|
1.6
|
L
 6.7%
H
1.5
1.6
|
L
 6.7%
H
1.5
1.6
|
L
 10.4%
H
1.2
1.6
|
L
 10.4%
H
1.2
1.9
|
L
 13.6%
H
1.2
2.7
|
L
 -11.7%
H
1.1
7.5
|
L
 -71.3%
H
1.1
8.2
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
621,632.7
|
200.5
|
L
 -0.4%
H
200.0
201.8
|
L
 -1.9%
H
199.5
207.3
|
L
 5.6%
H
182.4
207.3
|
L
 6.4%
H
182.4
212.7
|
L
 6.4%
H
182.4
212.7
|
L
 6.4%
H
182.4
212.7
|
L
 6.4%
H
182.4
212.7
|
L
 6.4%
H
182.4
212.7
|
| BridgeBio Pharma Inc |
|
15,039.9
|
77.6
|
L
 -0.2%
H
76.3
78.5
|
L
 4.6%
H
73.1
79.5
|
L
 11.8%
H
67.6
79.5
|
L
 1.7%
H
62.8
84.9
|
L
 126.6%
H
31.8
84.9
|
L
 426.3%
H
12.8
84.9
|
L
 41.2%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
8.2
|
4.9
|
L
 9.3%
H
4.3
5
|
L
 10.8%
H
4.2
5.2
|
L
 -40.4%
H
3.9
10.3
|
L
 -69.3%
H
3.9
19.3
|
L
 -69.1%
H
3.9
71.5
|
L
 -97.3%
H
3.9
203.4
|
L
 -99.8%
H
3.9
2873
|
L
H
3.9
3831.5
|
| BioCardia Inc |
|
13.0
|
1.2
|
L
H
1.2
1.2
|
L
 -1.7%
H
1.1
1.3
|
L
 -5.6%
H
1.1
1.4
|
L
 -15%
H
1.1
1.4
|
L
 -42.0%
H
1
3.2
|
L
 -96.0%
H
1
43.8
|
L
 -98.1%
H
1
76.5
|
L
 -99.0%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
2,380.1
|
9.5
|
L
 0.5%
H
9.3
9.6
|
L
 -3.0%
H
9.3
10.0
|
L
 15.5%
H
8.2
10.3
|
L
 32.4%
H
6.2
10.3
|
L
 28.2%
H
6
11.3
|
L
 17.6%
H
4.0
11.3
|
L
 -16.3%
H
4.0
20.0
|
L
 206.1%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
31.6
|
4.4
|
L
 -5.6%
H
4.3
4.7
|
L
 -1.6%
H
4.2
4.7
|
L
 3.3%
H
3.7
4.7
|
L
 -2.9%
H
3.6
5.2
|
L
 -98.8%
H
3.6
982
|
L
 -100.0%
H
3.6
11395.5
|
L
 -99.9%
H
3.6
18526.5
|
L
 -100.0%
H
3.6
83250
|
| Black Diamond Therapeutics Inc |
|
165.6
|
2.9
|
L
 0.7%
H
2.8
3.0
|
L
 15.6%
H
2.4
3.0
|
L
 36.3%
H
2
3.0
|
L
 8.2%
H
1.9
3.0
|
L
 103.5%
H
1.3
4.9
|
L
 94.0%
H
1.2
7.7
|
L
 -88.5%
H
1.2
29.0
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,088.3
|
30.3
|
L
 -1.2%
H
29.6
31.0
|
L
 19.2%
H
25.2
31.5
|
L
 20.5%
H
21.6
31.5
|
L
 -5.4%
H
21.6
35.3
|
L
 75.5%
H
15.4
36.4
|
L
 -3.0%
H
13.5
49.5
|
L
 -58.9%
H
13.5
138.5
|
L
H
13
138.5
|
| Biofrontera Inc |
|
12.5
|
1.1
|
L
 0.9%
H
1.0
1.1
|
L
 11.5%
H
1.0
1.1
|
L
 23.0%
H
0.8
1.1
|
L
 27.4%
H
0.7
1.1
|
L
 24.4%
H
0.5
1.2
|
L
 -91.0%
H
0.5
13.4
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
25,710.6
|
175.2
|
L
 -3.0%
H
174.9
180.0
|
L
 -2.6%
H
171.2
181.8
|
L
 -3.5%
H
168.6
192.3
|
L
 3.9%
H
160.4
202.4
|
L
 49.8%
H
114.7
202.4
|
L
 -39.2%
H
110.0
319.8
|
L
 -35.2%
H
110.0
468.6
|
L
 -29.2%
H
110.0
468.6
|
| BioVie Inc |
|
10.9
|
1.5
|
L
 2.8%
H
1.4
1.5
|
L
 -2.7%
H
1.4
1.5
|
L
 2.8%
H
1.2
1.5
|
L
 22.9%
H
1.1
1.5
|
L
 -82.3%
H
1.1
13.2
|
L
 -99.8%
H
1.1
869
|
L
 -99.9%
H
1.1
2386
|
L
 -99.8%
H
1.1
5625
|
| Biomea Fusion Inc |
|
140.3
|
1.9
|
L
 -1.5%
H
1.9
2
|
L
 10.2%
H
1.7
2
|
L
 42.7%
H
1.1
2
|
L
 38.6%
H
1.0
2
|
L
 12.1%
H
0.9
3.1
|
L
 -91.9%
H
0.9
43.7
|
L
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
10,375.8
|
54.0
|
L
 -2.4%
H
53.8
55.6
|
L
 -5.7%
H
53.8
57.1
|
L
 -7.8%
H
53.4
58.8
|
L
 -2.0%
H
53.4
66.3
|
L
 -10.1%
H
50.8
66.3
|
L
 -45.5%
H
50.8
100.4
|
L
 -31.5%
H
50.8
117.8
|
L
 -37.8%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
14.0
|
1.3
|
L
 -1.6%
H
1.2
1.3
|
L
 6.8%
H
1.1
1.3
|
L
 13.5%
H
1.1
1.5
|
L
 -17.1%
H
1.1
1.8
|
L
 -71.8%
H
1.1
5.5
|
L
 -88.4%
H
0.1
11.6
|
L
 -97.9%
H
0.1
91.2
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
458.0
|
13.4
|
L
 -1.7%
H
13.0
13.8
|
L
 20.9%
H
10.6
14.0
|
L
 13.8%
H
10.0
14.0
|
L
 14.2%
H
9.9
14.0
|
L
 -2.3%
H
9.9
17.2
|
L
 268.3%
H
1.9
17.2
|
L
 -83.4%
H
1.9
99.6
|
L
 -96.9%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
9.2
|
4.8
|
L
 -2.2%
H
4.7
4.9
|
L
 4.4%
H
4.5
5.1
|
L
 22.8%
H
4.0
5.1
|
L
 -31.2%
H
3.9
7.2
|
L
 -30.4%
H
3.9
9.2
|
L
 -83.6%
H
3.9
40.6
|
L
 -99.0%
H
3.9
552.6
|
L
H
3.9
861.4
|
| Bon Natural Life Ltd |
|
10.4
|
1.3
|
L
 -1.5%
H
1.3
1.3
|
L
 -3.0%
H
1.2
1.4
|
L
 -13.5%
H
1.1
1.6
|
L
 -26.4%
H
1.1
1.7
|
L
 -19.0%
H
1.1
3.4
|
L
 -99.7%
H
1.1
390
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
28.4
|
1.1
|
L
H
1.0
1.1
|
L
 -4.6%
H
1.0
1.2
|
L
 -29.5%
H
1.0
1.8
|
L
 -45.0%
H
1.0
2.1
|
L
 -42.3%
H
1.0
8.1
|
L
 -94.4%
H
0.2
29.6
|
L
 -97%
H
0.2
39
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
13.5
|
0.8
|
L
 -16.5%
H
0.7
0.8
|
L
 -32.7%
H
0.7
2.8
|
L
 40.7%
H
0.5
6.7
|
L
 -52.8%
H
0.4
6.7
|
L
 850%
H
0.1
6.7
|
L
 -29.0%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
68.3
|
1.7
|
L
 -1.8%
H
1.6
1.7
|
L
 -5.7%
H
1.6
1.8
|
L
 -1.8%
H
1.5
1.9
|
L
 -6.2%
H
1.2
1.9
|
L
 37.2%
H
1.2
3.4
|
L
 28.7%
H
0.7
4
|
L
 -83.5%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
358.3
|
5.1
|
L
 -2.7%
H
5.1
5.3
|
L
 3.2%
H
4.9
5.4
|
L
 7.5%
H
4.2
5.4
|
L
 -20.6%
H
4.2
7.3
|
L
 -34.0%
H
4.2
9.6
|
L
 -72.9%
H
4.2
28.9
|
L
 -82.8%
H
4.2
62.1
|
L
H
4.2
62.1
|
| Biodexa Pharma PLC (ADR) |
|
2.2
|
3.4
|
L
 0.3%
H
3.4
3.5
|
L
 -2.0%
H
2.9
3.5
|
L
 -17.3%
H
2.9
6.8
|
L
 -68.3%
H
2.9
11.5
|
L
 -95.3%
H
2.9
96.5
|
L
 -100.0%
H
2.9
793750
|
L
 -100.0%
H
2.9
180500000
|
L
 -100.0%
H
2.9
10000000000
|
| BeiGene Ltd (ADR) |
|
34,082.0
|
319.9
|
L
 3.2%
H
311.3
320.3
|
L
 2.5%
H
302.5
320.3
|
L
 12.6%
H
271.5
320.3
|
L
 -5.4%
H
271.5
372.7
|
L
 40.1%
H
228.9
385.2
|
L
 21.2%
H
127.0
385.2
|
L
 3.9%
H
118.2
426.6
|
L
 902.3%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
10.5
|
2.4
|
L
 1.7%
H
2.4
2.5
|
L
 5.2%
H
2.3
2.5
|
L
 -9.4%
H
2.2
2.8
|
L
 -16.0%
H
2.2
3.2
|
L
 -14.2%
H
2.2
7.8
|
L
 -94.5%
H
0.1
101.2
|
L
 -97.7%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,364.9
|
159.3
|
L
 -5.6%
H
158
167.6
|
L
 -10.9%
H
158
183.7
|
L
 -3.0%
H
146.6
183.7
|
L
 6.5%
H
146.6
200
|
L
 170.5%
H
53.6
200
|
L
 453.9%
H
11
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
25.1
|
4.7
|
L
 0.2%
H
4.6
4.7
|
L
 -0.9%
H
4.4
4.8
|
L
 2.6%
H
3.8
4.8
|
L
 13.7%
H
3.8
4.9
|
L
 -10.4%
H
3.6
21.4
|
L
 103.5%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
25,781.6
|
102.0
|
L
 2.5%
H
98.8
102.2
|
L
 10.7%
H
90.1
102.2
|
L
 11.8%
H
84.8
102.2
|
L
 -3.9%
H
79.5
124
|
L
 3.0%
H
79.5
124
|
L
 -21.4%
H
76.5
131.5
|
L
 -27.6%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.6
|
L
 1.7%
H
0.6
0.6
|
L
 3.5%
H
0.6
0.6
|
L
 -15.5%
H
0.6
0.8
|
L
 -34.1%
H
0.6
1.1
|
L
 -79.4%
H
0.6
6.2
|
L
 -66.5%
H
0.6
6.2
|
L
 -98.0%
H
0.6
99
|
L
 -98.5%
H
0.6
620
|
| Cabaletta Bio Inc |
|
391.9
|
3.5
|
L
 3.5%
H
3.4
3.6
|
L
 13.9%
H
3.0
3.6
|
L
 15.0%
H
2.5
3.6
|
L
 69.2%
H
2.0
3.8
|
L
 214.3%
H
1.1
3.8
|
L
 -54.9%
H
1.0
26.4
|
L
 -67.3%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
9.8
|
0.6
|
L
 -3.1%
H
0.6
0.6
|
L
H
0.6
0.7
|
L
 -25.3%
H
0.5
0.9
|
L
 -88.3%
H
0.5
6.0
|
L
 -61.3%
H
0.5
7.2
|
L
 -81.8%
H
0.5
8.6
|
L
 -99.1%
H
0.5
98.8
|
L
H
0.5
530.3
|
| Capricor Therapeutics Inc |
|
1,985.1
|
34.3
|
L
 -2.1%
H
33.4
35.5
|
L
 8.6%
H
29.6
36.0
|
L
 12.5%
H
27.5
36.0
|
L
 42.8%
H
21.1
36.5
|
L
 249.5%
H
4.3
40.4
|
L
 683.6%
H
2.7
40.4
|
L
 753.7%
H
2.6
40.4
|
L
 8.3%
H
0.9
54
|
| Tvardi Therapeutics Inc |
|
30.1
|
3.2
|
L
 -7.5%
H
3.2
3.5
|
L
 5.3%
H
2.8
3.5
|
L
 -18.1%
H
2.8
4.0
|
L
 -28.8%
H
2.8
4.9
|
L
 -79.9%
H
2.8
43.7
|
L
 -97.9%
H
2.8
168.1
|
L
 -99.7%
H
2.8
1034.3
|
L
 -98.8%
H
2.8
1067.3
|
| Crescent Biopharma Inc |
|
-
|
19.2
|
L
 -3.9%
H
19.1
19.9
|
L
 4.7%
H
17.3
20.7
|
L
 71.6%
H
9.9
20.7
|
L
 53.4%
H
8.7
20.7
|
L
 69.0%
H
7.6
21.4
|
L
 508.9%
H
3
21.4
|
L
 63.4%
H
0.9
21.4
|
L
 -67.5%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
278.1
|
2.9
|
L
 -1.4%
H
2.8
2.9
|
L
 -1.7%
H
2.5
3.0
|
L
 4.8%
H
2.3
3.0
|
L
 28.4%
H
1.7
3.8
|
L
 139.5%
H
1.1
3.8
|
L
 -14.9%
H
1.1
11.9
|
L
 -91.3%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
379.6
|
4.7
|
L
H
4.7
4.9
|
L
 3.0%
H
4.4
4.9
|
L
 -0.8%
H
4.2
5.0
|
L
 -24.9%
H
4.2
6.4
|
L
 -25.9%
H
4.2
14.7
|
L
 231.5%
H
1.3
14.7
|
L
 -44.4%
H
1.2
14.7
|
L
 2.2%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
894.6
|
14.8
|
L
 -1.1%
H
14.6
15.1
|
L
 -1.2%
H
13.8
15.3
|
L
 9.6%
H
12.4
15.7
|
L
 38.7%
H
10.5
16.7
|
L
 89.5%
H
5.7
16.7
|
L
 47.5%
H
5.7
30.2
|
L
 -58.8%
H
5.7
37.7
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
274.2
|
2.9
|
L
 0.4%
H
2.8
2.9
|
L
 26.6%
H
2.3
2.9
|
L
 29.5%
H
2.0
2.9
|
L
 37.4%
H
1.6
2.9
|
L
 110.1%
H
1.2
2.9
|
L
 360.3%
H
0.5
3.0
|
L
 -67.4%
H
0.5
9.2
|
L
 -57.7%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
98.3
|
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 25%
H
0.9
1.1
|
L
 4.8%
H
0.6
1.2
|
L
 -20.3%
H
0.6
1.5
|
L
 189.5%
H
0.2
3.8
|
L
 -38.2%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
284.8
|
1.9
|
L
 1.1%
H
1.9
2.0
|
L
 11.8%
H
1.6
2.0
|
L
 16.6%
H
1.5
2.0
|
L
 14.5%
H
1.5
2.6
|
L
 79.3%
H
0.7
2.6
|
L
 -75.9%
H
0.7
8.7
|
L
 -86.7%
H
0.7
19.3
|
L
 -91.3%
H
0.7
32.0
|
| Cingulate Inc |
|
64.4
|
5.3
|
L
 1.2%
H
5.1
5.3
|
L
 -10.1%
H
5.1
6.1
|
L
 -39.5%
H
5.1
11.9
|
L
 -3.3%
H
4.8
11.9
|
L
 21.5%
H
3.2
11.9
|
L
 426%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
75.0
|
6.4
|
L
 0.3%
H
6.3
6.6
|
L
 -0.5%
H
5.9
6.8
|
L
 11.4%
H
4.5
6.8
|
L
 24.7%
H
3.9
6.8
|
L
 107.5%
H
2.3
13.5
|
L
 -69.7%
H
2.3
21.8
|
L
 -97.4%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
12.9
|
3.1
|
L
 0.3%
H
2.9
3.1
|
L
 10.5%
H
2.7
3.1
|
L
 -4.7%
H
2.4
3.4
|
L
 -16.4%
H
2.4
4.0
|
L
 -65.4%
H
2.4
20.6
|
L
 -92.7%
H
2.4
133.5
|
L
 -99.3%
H
2.4
552
|
L
 -100.0%
H
2.4
14790
|
| Clearmind Medicine Inc |
|
1.8
|
0.7
|
L
 13.9%
H
0.6
0.9
|
L
 -43.5%
H
0.6
1.5
|
L
 -5.1%
H
0.6
1.5
|
L
 -71.9%
H
0.6
2.8
|
L
 -98.0%
H
0.6
52.4
|
L
 -99.9%
H
0.6
986.4
|
L
 -100.0%
H
0.6
788400
|
L
H
0.6
788400
|
| Compass Therapeutics Inc |
|
1,163.4
|
6.5
|
L
 10.4%
H
5.8
6.8
|
L
 19.6%
H
5
6.8
|
L
 24.5%
H
4.9
6.8
|
L
 11.4%
H
4.9
6.9
|
L
 280%
H
1.6
6.9
|
L
 108.4%
H
0.8
6.9
|
L
 -24%
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
2.2
|
2.8
|
L
H
2.6
2.9
|
L
 26.2%
H
2.1
2.9
|
L
 12.7%
H
2.1
3
|
L
 -62.7%
H
2.1
7.5
|
L
 -76.1%
H
2.1
34.8
|
L
 -100.0%
H
2.1
6600000
|
L
 -100.0%
H
2.1
120600000
|
L
H
2.1
256050000
|
| Context Therapeutics Inc |
|
210.4
|
2.3
|
L
 -8.8%
H
2.3
2.5
|
L
 -13.3%
H
2.3
2.8
|
L
 -31.9%
H
2.3
3.6
|
L
 50.7%
H
1.4
3.6
|
L
 172.6%
H
0.5
3.6
|
L
 269.4%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
21.2
|
1.5
|
L
 2.7%
H
1.5
1.6
|
L
 6.9%
H
1.2
1.6
|
L
 49.5%
H
1
2.0
|
L
 38.7%
H
0.9
2.0
|
L
 14.9%
H
0.9
2.7
|
L
 -35.3%
H
0.9
3.3
|
L
 -89.4%
H
0.9
41.5
|
L
 -99.4%
H
0.9
270.0
|
| Co-Diagnostics Inc |
|
5.3
|
1.5
|
L
 4.2%
H
1.4
1.5
|
L
 6.5%
H
1.4
1.5
|
L
 -47.1%
H
1.4
4.0
|
L
 -37.3%
H
1.4
4.0
|
L
 -85.9%
H
1.4
46.5
|
L
 -96.8%
H
1.4
66.9
|
L
 -99.4%
H
1.4
354.6
|
L
H
1.4
929.7
|
| Coeptis Therapeutics Holdings Inc |
|
86.3
|
13.9
|
L
 6.7%
H
12.5
14.0
|
L
 27.7%
H
10.9
14.0
|
L
 15.1%
H
9.8
14.0
|
L
 1.5%
H
9.8
15.9
|
L
 48.7%
H
6.3
21.4
|
L
 -47.1%
H
2.3
43.8
|
L
 40%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,856.1
|
36.1
|
L
 -0.7%
H
35.6
36.4
|
L
 -2.4%
H
35.6
37.6
|
L
 6.1%
H
32.7
39.4
|
L
 -8.1%
H
32.7
41.4
|
L
 640.9%
H
4.1
43.7
|
L
 251.3%
H
3.7
43.7
|
L
 297.4%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,093.1
|
33.7
|
L
 -3.4%
H
32.6
35.3
|
L
 0.9%
H
32.6
36.3
|
L
 -2.2%
H
31.5
37.1
|
L
 -28.1%
H
31.5
49.3
|
L
 24.4%
H
25.9
50.8
|
L
 47.1%
H
20.8
50.8
|
L
 43.8%
H
14.0
50.8
|
L
 81.9%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
4,675.1
|
44.0
|
L
 0.1%
H
43.2
44.3
|
L
 5.0%
H
41
44.4
|
L
 36.7%
H
32.0
50.4
|
L
 24.2%
H
28.7
50.4
|
L
 -36.8%
H
28.7
91
|
L
 98.2%
H
20.8
117.3
|
L
 91.6%
H
15.8
117.3
|
L
 796.9%
H
4.6
117.3
|
| Cosmos Health Inc |
|
15.3
|
0.4
|
L
 5.1%
H
0.3
0.4
|
L
 36.7%
H
0.3
0.5
|
L
 13.9%
H
0.3
0.5
|
L
 -24.1%
H
0.3
0.6
|
L
 17.1%
H
0.3
1.3
|
L
 -87.1%
H
0.3
4.1
|
L
 -99.7%
H
0.3
194.3
|
L
 -99.7%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
47.6
|
3.2
|
L
 -0.6%
H
3.1
3.4
|
L
 1.3%
H
3.0
3.4
|
L
 4.6%
H
2.7
3.9
|
L
 -33.2%
H
2.7
5.0
|
L
 -22.4%
H
1.9
6.3
|
L
 65.6%
H
1.0
7.3
|
L
 4.6%
H
1.0
7.5
|
L
 -31.5%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
3,152.0
|
25.8
|
L
 -0.2%
H
25.6
26.0
|
L
 2.0%
H
24.7
26.5
|
L
 11.1%
H
22.2
26.5
|
L
 12.4%
H
22.2
26.5
|
L
 11.1%
H
19.1
26.6
|
L
 45.9%
H
11.1
26.6
|
L
 477.4%
H
4.3
26.6
|
L
 2106.0%
H
0.5
26.6
|
| Corbus Pharma Holdings Inc |
|
178.8
|
10.1
|
L
 0.8%
H
9.9
10.3
|
L
 2.4%
H
9.6
10.7
|
L
 7.1%
H
8.1
10.7
|
L
 23.4%
H
7.2
10.7
|
L
 68.3%
H
5.8
20.6
|
L
 5.1%
H
3.0
61.9
|
L
 -80.9%
H
2.1
68.7
|
L
 -84.9%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
207.8
|
2.2
|
L
 -2.3%
H
2.1
2.2
|
L
 10.3%
H
1.9
2.2
|
L
 14.4%
H
1.7
2.2
|
L
 37.8%
H
1.4
2.2
|
L
 175.6%
H
0.7
3.5
|
L
 -53.1%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
155.2
|
1.4
|
L
 -2.8%
H
1.4
1.4
|
L
 7.8%
H
1.3
1.5
|
L
 36.3%
H
0.9
1.5
|
L
 44.8%
H
0.9
1.5
|
L
 31.1%
H
0.9
1.6
|
L
 167.3%
H
0.5
3.1
|
L
 -67.5%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
24.0
|
0.6
|
L
 -11.8%
H
0.6
0.7
|
L
 9.1%
H
0.5
0.8
|
L
 -36.8%
H
0.5
1.0
|
L
 -36.8%
H
0.5
1.2
|
L
 -53.5%
H
0.5
3.1
|
L
 -96.8%
H
0.5
20
|
L
 -99.8%
H
0.5
348
|
L
 -99.7%
H
0.5
372
|
| CorMedix Inc |
|
568.4
|
7.2
|
L
 -0.6%
H
7.1
7.3
|
L
 -0.6%
H
7.1
7.5
|
L
 11.5%
H
6.2
7.5
|
L
 2.6%
H
6.1
8.5
|
L
 -2.8%
H
6.1
17.4
|
L
 36.4%
H
2.6
17.4
|
L
 -6.0%
H
2.6
17.4
|
L
 -64.5%
H
0.9
22.7
|
| Crinetics Pharma Inc |
|
4,060.5
|
38.8
|
L
 -2.5%
H
38.7
40
|
L
 -3.0%
H
38.3
40.4
|
L
 3.4%
H
33.1
40.4
|
L
 -31.3%
H
33.1
57.0
|
L
 30.8%
H
25.8
58.0
|
L
 143.4%
H
15.8
62.5
|
L
 123.9%
H
15.2
62.5
|
L
H
10.6
62.5
|
| Cronos Grp Inc |
|
1,015.9
|
2.7
|
L
 -1.5%
H
2.7
2.7
|
L
 5.9%
H
2.5
2.7
|
L
 7.2%
H
2.4
2.7
|
L
 3.5%
H
2.4
2.8
|
L
 55.8%
H
1.7
3.4
|
L
 44.1%
H
1.6
3.4
|
L
 -67.1%
H
1.6
9.4
|
L
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
5,329.1
|
55.5
|
L
 -2.2%
H
54.6
57.2
|
L
 7.3%
H
49.5
59.4
|
L
 13.9%
H
44.1
59.4
|
L
 2.4%
H
44.1
61.8
|
L
 42.5%
H
33.0
78.5
|
L
 10.4%
H
30.0
91.1
|
L
 -55.2%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
1,265.8
|
15.1
|
L
 -0.3%
H
14.7
15.3
|
L
 1.3%
H
14.4
16.1
|
L
 -1.6%
H
13.0
16.1
|
L
 111.1%
H
7.1
27.0
|
L
 365.1%
H
3.1
27.0
|
L
 1349.0%
H
1.0
27.0
|
L
 442.1%
H
0.6
27.0
|
L
 -3.5%
H
0.6
27.0
|
| Champions Oncology Inc |
|
84.4
|
6.1
|
L
 -1.6%
H
5.8
6.1
|
L
 0.8%
H
5.7
6.2
|
L
 -0.3%
H
5.7
6.3
|
L
 -15.2%
H
5.5
7.7
|
L
 -24.4%
H
5.5
9.6
|
L
 26.7%
H
3.6
12.0
|
L
 -46.1%
H
3.6
12.0
|
L
 66.6%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
1,072.2
|
5.0
|
L
 8.8%
H
4.6
5.1
|
L
 16.7%
H
4.2
5.1
|
L
 6.0%
H
4.1
8.2
|
L
 16.7%
H
4.1
8.2
|
L
 687.3%
H
0.6
8.2
|
L
 198.8%
H
0.4
8.2
|
L
 -35.2%
H
0.4
10.1
|
L
 -63.3%
H
0.4
35
|
| Cue Biopharma Inc |
|
61.5
|
0.6
|
L
 -12.5%
H
0.6
0.8
|
L
 133.3%
H
0.2
0.8
|
L
 125%
H
0.2
0.8
|
L
 125%
H
0.2
0.8
|
L
 -21.3%
H
0.2
1.0
|
L
 -81.9%
H
0.2
5.1
|
L
 -95.1%
H
0.2
18.4
|
L
H
0.2
31.7
|
| Cadrenal Therapeutics Inc |
|
11.8
|
4.7
|
L
 -1.9%
H
4.7
4.9
|
L
 -2.7%
H
4.5
5.2
|
L
 -36.2%
H
4.2
7.9
|
L
 -42.4%
H
4.2
9.0
|
L
 -71.1%
H
4.2
17.5
|
L
 247.1%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
5.6
|
1.0
|
L
 -1.9%
H
1
1.1
|
L
 3.0%
H
1.0
1.1
|
L
 24.4%
H
0.8
1.2
|
L
 -28.7%
H
0.7
1.7
|
L
 -98.1%
H
0.7
100.8
|
L
 -100.0%
H
0.7
3168
|
L
 -100.0%
H
0.7
28620
|
L
 -100.0%
H
0.7
784800
|
| Cyclerion Therapeutics Inc |
|
13.1
|
3.0
|
L
 -0.3%
H
2.9
3.0
|
L
 4.5%
H
2.8
3.8
|
L
 108.3%
H
1.3
8.5
|
L
 122.1%
H
1.0
8.5
|
L
 12.3%
H
1.0
8.5
|
L
 -47.9%
H
1.0
8.5
|
L
 -94.0%
H
1.0
97.2
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
7,988.3
|
64.9
|
L
 -0.8%
H
64.0
65.6
|
L
 -1.4%
H
64.0
67.9
|
L
 8.0%
H
59.0
68.7
|
L
 2.2%
H
58.4
70.4
|
L
 68.2%
H
29.3
71.0
|
L
 86.5%
H
26.0
110
|
L
 160.8%
H
17.7
110
|
L
 710.8%
H
5.8
110
|
| Cellectis (ADR) |
|
424.5
|
4.2
|
L
 3.2%
H
4.1
4.4
|
L
 18.9%
H
3.5
4.6
|
L
 23.4%
H
3.0
4.6
|
L
 3.4%
H
3.0
4.6
|
L
 189.0%
H
1.3
5.5
|
L
 106.9%
H
1.0
5.5
|
L
 -78.1%
H
1.0
20.4
|
L
 -85.1%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
12.0
|
1.7
|
L
 -0.6%
H
1.6
1.7
|
L
 -2.3%
H
1.6
1.8
|
L
 -8.7%
H
1.5
2.2
|
L
 -1.8%
H
1.4
2.2
|
L
 -65.5%
H
1.4
5.9
|
L
 -74.2%
H
1.4
10.2
|
L
 -98.8%
H
1.4
184.7
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
847.0
|
6.6
|
L
 10.2%
H
5.8
6.8
|
L
 14.9%
H
5.5
6.8
|
L
 2.8%
H
4.9
6.8
|
L
 -10.1%
H
4.9
8.9
|
L
 117.6%
H
2.3
8.9
|
L
 -33.9%
H
2.3
12.8
|
L
 -80.7%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Centessa Pharma PLC (ADR) |
|
6,123.1
|
39.6
|
L
 -0.1%
H
39.5
39.6
|
L
 0.2%
H
39.2
39.8
|
L
 50.4%
H
25.2
40.3
|
L
 76.7%
H
21.5
40.3
|
L
 231.6%
H
11.0
40.3
|
L
 884.8%
H
3.8
40.3
|
L
H
2.9
40.3
|
L
H
2.9
40.3
|
| Connect Biopharma Holdings Ltd (ADR) |
|
166.6
|
3.0
|
L
 2.1%
H
3.0
3.1
|
L
 13.7%
H
2.6
3.2
|
L
 11.2%
H
2.6
3.8
|
L
 34.7%
H
2.1
3.8
|
L
 260.2%
H
0.7
3.8
|
L
 184.8%
H
0.5
3.8
|
L
 -82.7%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
35.1
|
2.4
|
L
 34.6%
H
1.8
2.5
|
L
 30.3%
H
1.7
2.5
|
L
 67.4%
H
1.3
2.5
|
L
 23.6%
H
1.3
2.5
|
L
 -18.3%
H
1.3
9.2
|
L
 -80.1%
H
0.3
13.2
|
L
 -86.5%
H
0.3
30.1
|
L
 -99.4%
H
0.3
519.6
|
| Day One Biopharma Inc |
|
2,216.8
|
21.5
|
L
 -0.1%
H
21.5
21.5
|
L
 0.1%
H
21.5
21.5
|
L
 0.7%
H
21.3
21.5
|
L
 104.4%
H
9.8
21.5
|
L
 198.5%
H
5.6
21.5
|
L
 73.9%
H
5.6
21.5
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
142.1
|
5.2
|
L
 -1.9%
H
5.1
5.3
|
L
 -2.4%
H
5.0
5.4
|
L
 -28.0%
H
4.3
7.8
|
L
 -37.8%
H
4.3
9.6
|
L
 -15.9%
H
4.3
9.6
|
L
 246.7%
H
1.0
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
4.0
|
L
H
4.0
4.2
|
L
H
3.8
4.2
|
L
 -4.9%
H
3.5
4.6
|
L
 -42.9%
H
3.5
7.4
|
L
 -54.0%
H
3.5
13.1
|
L
 -37.2%
H
3.5
14.4
|
L
 -92.2%
H
3.5
64.1
|
L
 -100.0%
H
3.5
17437.5
|
| DiaMedica Therapeutics Inc |
|
354.5
|
6.6
|
L
H
6.4
6.7
|
L
 6.3%
H
5.7
6.7
|
L
 -9.6%
H
5.7
7.5
|
L
 -23.0%
H
5.7
9.0
|
L
 87.5%
H
3.3
10.4
|
L
 311.3%
H
1.5
10.4
|
L
 -33.1%
H
1.1
10.4
|
L
 169.7%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,289.2
|
20.7
|
L
 -4.3%
H
20.6
21.8
|
L
 5.7%
H
19.0
21.8
|
L
 0.8%
H
17.9
23.5
|
L
 10.4%
H
17.2
23.8
|
L
 57.5%
H
12.3
23.8
|
L
 -16.1%
H
10.6
33.3
|
L
 -63.0%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
66.5
|
2.9
|
L
 -3.9%
H
2.9
3.1
|
L
 2.1%
H
2.8
3.2
|
L
 -4.2%
H
2.7
3.4
|
L
 -29.3%
H
2.7
4.4
|
L
 -25.6%
H
2.7
8.4
|
L
 -16.7%
H
0.8
13.6
|
L
 -80.7%
H
0.8
20.6
|
L
 -98.1%
H
0.8
308.4
|
| DarioHealth Corp |
|
54.0
|
7.4
|
L
 -1.6%
H
6.4
7.4
|
L
 8.4%
H
6.4
8.0
|
L
 -17.9%
H
6.2
9.6
|
L
 -39.5%
H
6.2
12.5
|
L
 -47.5%
H
5.9
17.7
|
L
 -90.0%
H
5.9
91.6
|
L
 -98.1%
H
5.9
476
|
L
 -99.7%
H
5.9
2360.0
|
| Dermata Therapeutics Inc |
|
5.3
|
1.3
|
L
 5.6%
H
1.3
1.4
|
L
 3.9%
H
1.2
1.4
|
L
 11.8%
H
1.1
1.8
|
L
 -40.9%
H
1.1
4.7
|
L
 70.5%
H
0.6
7.1
|
L
 5.6%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
854.9
|
87.4
|
L
 -2.5%
H
86
89.5
|
L
 5.6%
H
79.9
90.4
|
L
 21.3%
H
66.2
90.4
|
L
 -2.9%
H
66.2
91
|
L
 169.5%
H
23.2
123.8
|
L
 4161.0%
H
0.9
123.8
|
L
 347.9%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
766.0
|
12.4
|
L
 -2.6%
H
12.2
12.8
|
L
 -2.0%
H
11.9
13.0
|
L
 22.7%
H
9.9
13.0
|
L
 32.7%
H
9.0
13.0
|
L
 274.1%
H
3.1
13.0
|
L
 139.3%
H
1.9
13.0
|
L
 -47.6%
H
1.9
29.2
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
192.2
|
7.5
|
L
 -2.7%
H
7.3
7.7
|
L
 24.4%
H
6.0
7.7
|
L
 31.4%
H
5.4
7.7
|
L
 91.0%
H
3.5
7.7
|
L
 35.0%
H
3.5
8.8
|
L
 786.9%
H
0.3
19.4
|
L
 -16.7%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,293.9
|
20.0
|
L
 -0.1%
H
19.5
20.4
|
L
 8.6%
H
18.1
21.4
|
L
 11.4%
H
16.9
21.4
|
L
 21.6%
H
14
21.4
|
L
 154.3%
H
7.4
25
|
L
 119.3%
H
6.4
47.5
|
L
 13.9%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
1,216.2
|
20.6
|
L
 -3.3%
H
20.5
21.1
|
L
 -4.5%
H
20.4
23.0
|
L
 0.1%
H
18.9
23.0
|
L
 9.3%
H
18.6
25.4
|
L
 179.6%
H
7.3
26.2
|
L
 16.8%
H
0.5
26.2
|
L
 -67.1%
H
0.5
68.8
|
L
 -94.2%
H
0.5
505.7
|
| Editas Medicine Inc |
|
324.9
|
3.3
|
L
 -1.5%
H
3.2
3.4
|
L
 20.3%
H
2.7
3.6
|
L
 36.1%
H
2.1
3.6
|
L
 58.9%
H
1.7
3.6
|
L
 145.9%
H
1.2
4.5
|
L
 -56.3%
H
0.9
11.9
|
L
 -91.9%
H
0.9
73.0
|
L
 -91.7%
H
0.9
100.0
|
| Edesa Biotech Inc |
|
46.0
|
5.2
|
L
 -3.4%
H
5.1
5.8
|
L
 -13.1%
H
5.1
6.4
|
L
 -13.1%
H
4.9
9.4
|
L
 264.8%
H
0.7
9.4
|
L
 129.2%
H
0.7
9.4
|
L
 -29.5%
H
0.7
9.4
|
L
 -86.0%
H
0.7
84
|
L
 -99.5%
H
0.7
1669.9
|
| Eledon Pharma Inc |
|
276.9
|
3.7
|
L
 10.6%
H
3.3
3.7
|
L
 16.6%
H
3.1
3.7
|
L
 35.7%
H
2.7
3.7
|
L
 76.3%
H
2.0
3.7
|
L
 21.3%
H
1.4
4.6
|
L
 49.6%
H
1.1
5.4
|
L
 -67.8%
H
1.1
11.7
|
L
 -99.7%
H
1.1
1296
|
| Elicio Therapeutics Inc |
|
234.4
|
12.7
|
L
 8.2%
H
11.4
12.9
|
L
 25.8%
H
10
12.9
|
L
 4.4%
H
9.9
12.9
|
L
 63.1%
H
7.4
14.9
|
L
 155.8%
H
4.7
14.9
|
L
 119.7%
H
3.0
24.4
|
L
 -91.4%
H
3.0
162.6
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
2,713.7
|
45.4
|
L
 3.3%
H
42.6
45.8
|
L
 5.7%
H
42.6
46.3
|
L
 63.4%
H
26.7
46.3
|
L
 80.3%
H
24.8
46.3
|
L
 166.2%
H
14.8
46.3
|
L
 151.7%
H
9.8
46.3
|
L
 53.7%
H
3.9
46.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
424.7
|
8.9
|
L
 2.8%
H
8.4
9.0
|
L
 25.2%
H
7.1
9.3
|
L
 26.5%
H
5.9
9.3
|
L
 135.8%
H
3.9
9.3
|
L
 553.7%
H
1.1
9.3
|
L
 182.2%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
203.4
|
0.9
|
L
 3.7%
H
0.8
0.9
|
L
 -8.6%
H
0.7
1.0
|
L
 -18.3%
H
0.7
1.3
|
L
 -8.6%
H
0.7
1.3
|
L
 -4.5%
H
0.7
2.1
|
L
 -70.8%
H
0.7
4.6
|
L
 -92.4%
H
0.7
14.0
|
L
 -99.2%
H
0.7
120
|
| Enochian Biosciences Inc |
|
-
|
0.3
|
L
 -5.9%
H
0.3
0.4
|
L
 -11.1%
H
0.3
0.4
|
L
 77.8%
H
0.2
1.0
|
L
 -65.2%
H
0.2
1.1
|
L
H
0.1
1.7
|
L
 -73.8%
H
0.1
2.3
|
L
 -90.0%
H
0.1
13.8
|
L
 -83.6%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
4.7
|
0.5
|
L
 -5.6%
H
0.5
0.5
|
L
 2%
H
0.5
0.6
|
L
 24.4%
H
0.4
0.7
|
L
 -43.3%
H
0.3
1.0
|
L
 -77.2%
H
0.3
4.9
|
L
 -87.2%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
409.2
|
14.1
|
L
 -3.1%
H
14.0
14.5
|
L
 2.4%
H
13.3
14.9
|
L
 11.0%
H
11.8
14.9
|
L
 5.6%
H
11.8
15.7
|
L
 173.8%
H
4.7
17.2
|
L
 -61.4%
H
4.1
38.8
|
L
 -72.8%
H
4.1
102
|
L
 -55.2%
H
4.1
127.8
|
| Entera Bio Ltd |
|
63.7
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
H
1.1
1.3
|
L
 -7.9%
H
0.9
1.5
|
L
 -26.0%
H
0.9
1.7
|
L
 -35.4%
H
0.9
3.2
|
L
 36.0%
H
0.5
3.4
|
L
 -64.5%
H
0.5
8.7
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
4.4
|
2.3
|
L
 15.3%
H
2.0
3.1
|
L
 19.4%
H
1.9
3.1
|
L
 23.2%
H
1.8
3.1
|
L
 -42.7%
H
1.8
4.7
|
L
 -84.3%
H
1.8
17.8
|
L
 -99.1%
H
1.8
1256.4
|
L
 -100.0%
H
1.8
33660
|
L
 -100.0%
H
1.8
12150000
|
| Evolus Inc |
|
294.1
|
4.5
|
L
 -2.4%
H
4.5
4.6
|
L
 10.5%
H
4.0
4.6
|
L
 -9.8%
H
3.9
5.2
|
L
 -9.6%
H
3.9
6.3
|
L
 -55.8%
H
3.9
12.3
|
L
 -46.1%
H
3.9
17.8
|
L
 -59.9%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
125.8
|
2.0
|
L
 -2.9%
H
2.0
2.1
|
L
 10.6%
H
1.7
2.2
|
L
 -19.4%
H
1.6
2.7
|
L
 87.7%
H
1.1
2.7
|
L
 332.6%
H
0.3
2.7
|
L
 180.3%
H
0.3
3.3
|
L
 -69.8%
H
0.3
7.8
|
L
H
0.3
27.1
|
| Erasca Inc |
|
5,656.6
|
18.2
|
L
H
17.6
18.5
|
L
 7.4%
H
14
19.4
|
L
 33.6%
H
12.9
19.4
|
L
 90.4%
H
8.8
19.4
|
L
 1429.4%
H
1.1
19.4
|
L
 523.3%
H
1.0
19.4
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
521.3
|
2.0
|
L
 -6.5%
H
2.0
2.2
|
L
 -12.9%
H
2.0
2.3
|
L
 -16.8%
H
2.0
2.9
|
L
 -35.1%
H
2.0
3.7
|
L
 103%
H
0.7
4.2
|
L
 62.4%
H
0.7
4.2
|
L
 -92.5%
H
0.7
28.8
|
L
 -89.1%
H
0.7
82.7
|
| Eton Pharma Inc |
|
662.2
|
24.3
|
L
 -10.0%
H
24.2
26.2
|
L
 -8.1%
H
24.2
27.3
|
L
 28.2%
H
18.6
27.3
|
L
 57.5%
H
14.3
27.3
|
L
 71.0%
H
13.1
27.3
|
L
 589.5%
H
2.4
27.3
|
L
 183.5%
H
2.0
27.3
|
L
H
2.0
27.3
|
| Edgewise Therapeutics Inc |
|
3,564.6
|
33.2
|
L
 -1.4%
H
32.9
34.1
|
L
 0.6%
H
32.3
34.8
|
L
 12.3%
H
28.9
34.8
|
L
 24.9%
H
25.9
34.8
|
L
 155.2%
H
12.2
34.8
|
L
 471.9%
H
5.1
38.1
|
L
 19.1%
H
5.1
38.1
|
L
H
5.1
40.5
|
| Exelixis Inc |
|
11,505.1
|
44.3
|
L
 0.1%
H
44.0
44.7
|
L
 0.2%
H
43.8
46.1
|
L
 7.4%
H
40.8
46.1
|
L
 -2.5%
H
39.7
46.1
|
L
 21.2%
H
33.8
49.6
|
L
 127.6%
H
18.1
49.6
|
L
 85.0%
H
14.9
49.6
|
L
 918.4%
H
4.2
49.6
|
| Hyperion DeFi Inc |
|
44.7
|
3.9
|
L
 1.6%
H
3.7
4
|
L
 22.1%
H
3.1
4
|
L
 9.8%
H
2.9
4.0
|
L
 17.0%
H
2.8
4.5
|
L
 250%
H
1.0
17.2
|
L
 -98.9%
H
0.0
468
|
L
 -99.1%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,231.5
|
14.8
|
L
 0.9%
H
14.5
14.8
|
L
 4.2%
H
13.9
14.9
|
L
 11.8%
H
11.8
14.9
|
L
 -6.8%
H
11.8
18.9
|
L
 160.3%
H
5.3
19.1
|
L
 240.9%
H
3.9
31.0
|
L
 53.9%
H
2.2
31.0
|
L
 -50.1%
H
2.2
42.5
|
| Evaxion Biotech A/S (ADR) |
|
34.0
|
4.1
|
L
 -1.5%
H
4.0
4.3
|
L
 0.5%
H
3.9
4.5
|
L
 -4.2%
H
3.3
4.5
|
L
 -14.8%
H
2.9
4.9
|
L
 202.2%
H
1.3
12.2
|
L
 -73.8%
H
0.8
18.5
|
L
 -94.7%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Evotec SE (ADR) |
|
1,140.2
|
3.2
|
L
H
3.2
3.3
|
L
 19.3%
H
2.6
3.3
|
L
 39.0%
H
2.3
3.3
|
L
 -11.3%
H
2.3
3.8
|
L
 -4.8%
H
2.3
4.8
|
L
 -69.5%
H
2.3
13.5
|
L
 -84.0%
H
2.3
26.6
|
L
 63.8%
H
2.0
26.6
|
| Fate Therapeutics Inc |
|
157.0
|
1.4
|
L
 4.7%
H
1.3
1.4
|
L
 14.4%
H
1.2
1.5
|
L
 15.4%
H
1.0
1.5
|
L
 28.6%
H
1.0
1.7
|
L
 20.5%
H
0.9
1.9
|
L
 -77.5%
H
0.7
8.8
|
L
 -98.4%
H
0.7
97.4
|
L
 -38.1%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
75.4
|
2.3
|
L
 -3.7%
H
2.3
2.5
|
L
 1.3%
H
2.3
2.5
|
L
 -24.5%
H
2.2
3.2
|
L
 -32.8%
H
2.2
4.2
|
L
 54.0%
H
1.5
4.5
|
L
 -80.7%
H
1.2
12.6
|
L
 -96.5%
H
1.2
71.9
|
L
 -95.7%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
610.6
|
31.2
|
L
 -0.4%
H
29.8
31.2
|
L
 18.6%
H
27.9
35.8
|
L
 16.5%
H
22.0
35.8
|
L
 -4.7%
H
22.0
35.8
|
L
 433.6%
H
4.9
35.8
|
L
 15.4%
H
4.1
35.8
|
L
 -96.6%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
496.7
|
9.7
|
L
 -0.4%
H
9.5
9.9
|
L
 -3.7%
H
9.4
10.2
|
L
 16.8%
H
8.2
10.9
|
L
 27.9%
H
7.3
10.9
|
L
 213.9%
H
2.9
12.3
|
L
 -39.8%
H
2.2
36.3
|
L
 -73.2%
H
2.2
39.9
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
212.0
|
6.2
|
L
 -5.4%
H
6.2
6.6
|
L
 -5.2%
H
5.7
6.6
|
L
 -18.2%
H
5.7
8.1
|
L
 -17.6%
H
5.7
9.2
|
L
 17.1%
H
5.0
9.9
|
L
 -27.0%
H
4.0
11.9
|
L
 -4.4%
H
3.8
11.9
|
L
 253.4%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
29.1
|
7.2
|
L
 0.8%
H
7.2
7.3
|
L
 -1.6%
H
7.0
7.5
|
L
 3.0%
H
6.3
7.5
|
L
 -20.8%
H
6.3
9.4
|
L
 -3.0%
H
4.9
12.6
|
L
 -98.5%
H
4.5
522.5
|
L
 -98.5%
H
4.5
753.1
|
L
 -98.6%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
283.5
|
4.8
|
L
 -0.8%
H
4.8
4.9
|
L
 -1.2%
H
4.5
5.0
|
L
 -1.4%
H
4.4
5.4
|
L
 -23.1%
H
4.4
6.4
|
L
 35.3%
H
3.3
7.0
|
L
 -32.5%
H
2.7
10.2
|
L
 -59.0%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
83.7
|
5.7
|
L
 -6.1%
H
5.6
6.2
|
L
 4.6%
H
4.8
6.3
|
L
 -16.1%
H
4.8
8.0
|
L
 58.9%
H
3.4
8.0
|
L
 183.2%
H
1.3
8.0
|
L
 -69.1%
H
1.3
53.8
|
L
 -95.5%
H
1.3
160.2
|
L
H
1.3
572.4
|
| ZeroStack Corp |
|
16.2
|
6.7
|
L
 9.0%
H
6.4
7
|
L
 34.9%
H
4.8
7
|
L
 -20.6%
H
4.8
9.7
|
L
 1.7%
H
4.8
15.0
|
L
 -64.3%
H
4.8
47
|
L
 -96.6%
H
4.8
213.7
|
L
H
4.8
16731
|
L
H
4.8
16731
|
| Amicus Therapeutics Inc |
|
4,540.5
|
14.5
|
L
H
14.5
14.5
|
L
H
14.5
14.5
|
L
 0.6%
H
14.4
14.5
|
L
 1.1%
H
14.3
14.5
|
L
 109.6%
H
5.5
14.5
|
L
 26.8%
H
5.5
14.6
|
L
 40.0%
H
5.5
14.6
|
L
 86.6%
H
4.4
25.4
|
| Frequency Therapeutics Inc |
|
-
|
13.7
|
L
 -1.8%
H
13.3
14.1
|
L
 1.6%
H
12.5
14.5
|
L
 6.9%
H
9.9
15.6
|
L
 55.5%
H
8.3
15.6
|
L
 -9.5%
H
5.2
55.9
|
L
 -39.9%
H
5.2
55.9
|
L
 -97.2%
H
5.2
609.5
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
531.5
|
8.0
|
L
 -3.3%
H
7.9
8.3
|
L
 1.0%
H
7.4
8.3
|
L
 4.3%
H
6.5
8.3
|
L
 -23.1%
H
6.5
12.0
|
L
 162.5%
H
3.0
15.7
|
L
 231.1%
H
2.3
15.7
|
L
 -33.1%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
3.6
|
2.3
|
L
 10.7%
H
2.1
2.3
|
L
 9.6%
H
2
2.3
|
L
 0.9%
H
1.9
2.6
|
L
 -42.4%
H
1.9
4.1
|
L
 442.9%
H
0.4
5.8
|
L
 -95.7%
H
0.4
73
|
L
 -100.0%
H
0.4
44937.1
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
148.1
|
2.3
|
L
 -12.1%
H
2.2
2.6
|
L
 1.4%
H
2.2
2.6
|
L
 -27.2%
H
2.2
3.3
|
L
 -28.6%
H
2.2
3.6
|
L
 67.9%
H
1.2
7.1
|
L
 11.9%
H
0.7
7.1
|
L
 0.9%
H
0.7
7.1
|
L
 34.7%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
89.2
|
2.1
|
L
 -1.9%
H
2.1
2.2
|
L
 16.7%
H
1.8
2.2
|
L
 -13.6%
H
1.7
2.7
|
L
 11.7%
H
1.6
3.1
|
L
 16.7%
H
1.4
4.3
|
L
 -56.2%
H
0.9
6.2
|
L
 -85.1%
H
0.9
14.9
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
11.8
|
1
|
L
H
1
1.0
|
L
H
0.9
1.0
|
L
 -5.7%
H
0.9
1.1
|
L
 7.5%
H
0.7
1.3
|
L
 -57.3%
H
0.7
3.7
|
L
 -75%
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
1,076.7
|
1.7
|
L
 -0.6%
H
1.7
1.7
|
L
 -1.8%
H
1.7
1.8
|
L
 6.3%
H
1.4
1.8
|
L
 29.2%
H
1.3
2.0
|
L
 34.4%
H
1.0
2.0
|
L
 -14.7%
H
1.0
5.3
|
L
 11.3%
H
1.0
5.3
|
L
 -48.5%
H
0.8
7.0
|
| GH Research PLC |
|
1,089.2
|
17.6
|
L
 3.3%
H
16.5
18.3
|
L
 17.1%
H
14.9
18.3
|
L
 17.5%
H
12.8
18.3
|
L
 3.5%
H
12.8
18.3
|
L
 95.3%
H
8.5
19.5
|
L
 117.9%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Gilead Sciences |
|
171,857.1
|
138.5
|
L
 -0.9%
H
137.8
140.3
|
L
 -2.2%
H
137.0
143.0
|
L
 -4.5%
H
133.9
146.7
|
L
 14.2%
H
122.1
157.3
|
L
 31.0%
H
93.4
157.3
|
L
 66.8%
H
62.1
157.3
|
L
 110.5%
H
57.2
157.3
|
L
 40.9%
H
56.6
157.3
|
| Galmed Pharma Ltd |
|
4.8
|
0.7
|
L
 2.9%
H
0.7
0.8
|
L
 16.1%
H
0.7
1.3
|
L
 14.3%
H
0.4
1.3
|
L
 -7.7%
H
0.4
1.3
|
L
 -48.9%
H
0.4
2.7
|
L
 -98.7%
H
0.2
93.6
|
L
 -99.9%
H
0.2
734.4
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
374.1
|
27
|
L
 4.2%
H
25
27.2
|
L
 11.6%
H
24.0
28.2
|
L
 1.0%
H
20.5
30.3
|
L
 -0.7%
H
20
34.1
|
L
 201.7%
H
7.8
34.1
|
L
 128.6%
H
7.6
34.1
|
L
 -17.2%
H
6.8
49.0
|
L
H
3.3
158.1
|
| Galecto Inc |
|
1,623.4
|
26.9
|
L
 1.2%
H
26.3
28.2
|
L
 5.2%
H
24.8
28.6
|
L
 2.2%
H
16.5
28.6
|
L
 12.4%
H
16.5
34.0
|
L
 947.5%
H
2.4
38.3
|
L
 1316.8%
H
0.5
38.3
|
L
 339.9%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,480.3
|
18.5
|
L
 1.5%
H
18.1
18.6
|
L
 8.1%
H
16.9
18.6
|
L
 15.5%
H
14.2
18.6
|
L
 -23.2%
H
14.2
25.4
|
L
 317.6%
H
3.5
25.8
|
L
 170.1%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
1,287.4
|
20.0
|
L
 2.2%
H
19.1
20.7
|
L
 8.9%
H
17.3
20.7
|
L
 78.4%
H
9.9
20.7
|
L
 59.6%
H
8.7
20.7
|
L
 -12.5%
H
8.7
28.8
|
L
 -86.4%
H
8.7
353
|
L
 -92.2%
H
8.7
416
|
L
 -96.8%
H
8.7
2605
|
| Genelux Corp |
|
125.0
|
2.8
|
L
 -1.8%
H
2.7
2.9
|
L
 5.7%
H
2.3
2.9
|
L
 7.3%
H
2.3
2.9
|
L
 9.0%
H
2.3
3.1
|
L
 13.4%
H
2.3
8.5
|
L
 -90.3%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
11.8
|
1.3
|
L
 1.6%
H
1.3
1.4
|
L
 -0.8%
H
1.2
1.4
|
L
 -35.3%
H
1.2
2.1
|
L
 -60.6%
H
1.2
3.4
|
L
 400%
H
0.1
13.0
|
L
 56.6%
H
0.1
13.0
|
L
 -67.4%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
103.3
|
0.4
|
L
 -2.2%
H
0.4
0.5
|
L
 25.7%
H
0.3
0.5
|
L
H
0.3
0.5
|
L
 -82.0%
H
0.3
3
|
L
 -47.0%
H
0.3
3.9
|
L
 -57.7%
H
0.3
3.9
|
L
 -95.0%
H
0.3
15.2
|
L
H
0.3
27.2
|
| Geovax Labs Inc |
|
2.7
|
1.2
|
L
 -4.7%
H
1.2
1.3
|
L
 3.4%
H
1.1
1.4
|
L
 -29.1%
H
1.1
1.8
|
L
 -57.2%
H
1.1
3.4
|
L
 -94.3%
H
1.1
34.8
|
L
 -99.5%
H
1.1
288.4
|
L
 -99.9%
H
1.1
2812.5
|
L
 -100.0%
H
1.1
379518072.3
|
| Graphite Bio Inc |
|
557.9
|
9.6
|
L
 -3.2%
H
9.5
10.2
|
L
 1.4%
H
9.0
10.2
|
L
 -21.2%
H
8.3
12.7
|
L
 -47.2%
H
8.3
21.8
|
L
 -64.3%
H
8.3
50.4
|
L
 -92.1%
H
8.3
413
|
L
H
8.3
1666
|
L
H
8.3
1666
|
| GT Biopharma Inc |
|
12.3
|
0.4
|
L
H
0.4
0.4
|
L
 -2.5%
H
0.4
0.4
|
L
 -7.1%
H
0.4
0.5
|
L
 -46.6%
H
0.4
0.8
|
L
 -83.5%
H
0.4
3.9
|
L
 -17.0%
H
0.2
10.7
|
L
 -95.7%
H
0.2
19.7
|
L
 -100.0%
H
0.2
2830.5
|
| Galapagos NV (ADR) |
|
1,903.1
|
28.9
|
L
 -1.0%
H
28.7
29.2
|
L
 0.0%
H
28.0
29.3
|
L
 -8.9%
H
28.0
33.4
|
L
 -15.1%
H
28.0
36.2
|
L
 20.9%
H
23.9
37.8
|
L
 -24.7%
H
22.4
45.2
|
L
 -63.6%
H
22.4
83.8
|
L
 -34.5%
H
22.4
274.0
|
| Genmab (ADR) |
|
17,355.3
|
28.3
|
L
 -3.5%
H
28.2
29.1
|
L
 -0.5%
H
27.9
29.4
|
L
 8.2%
H
25.0
29.4
|
L
 -16.5%
H
25.0
34.7
|
L
 44.9%
H
18.9
35.4
|
L
 -32.0%
H
17.2
43
|
L
 -19.2%
H
17.2
49.1
|
L
 100.6%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
17.0
|
0.7
|
L
 1.4%
H
0.7
0.8
|
L
 1.4%
H
0.6
0.8
|
L
 -18.2%
H
0.6
0.9
|
L
 -47.8%
H
0.6
1.7
|
L
 -81.2%
H
0.6
10
|
L
 -88.6%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Grifols SA (ADR) - Level III |
|
5,852.9
|
8.6
|
L
 -1.0%
H
8.6
8.7
|
L
 2.5%
H
7.9
8.8
|
L
 10.1%
H
7.4
8.8
|
L
 -3.7%
H
7.4
9.8
|
L
 23.0%
H
6.9
11.1
|
L
 14.2%
H
5.3
12.2
|
L
 -52.9%
H
5.3
19.1
|
L
 -43.7%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
7,888.0
|
66.6
|
L
 -2.2%
H
66.4
68.8
|
L
 1.8%
H
65.2
68.8
|
L
 4.6%
H
61.3
68.8
|
L
 -7.3%
H
61.3
82.2
|
L
 8.7%
H
47.5
82.2
|
L
 86.8%
H
29.9
82.2
|
L
 44.1%
H
29.9
82.2
|
L
 456.2%
H
7.7
82.2
|
| HCW Biologics Inc |
|
2.7
|
0.4
|
L
 -2.4%
H
0.4
0.4
|
L
 21.2%
H
0.3
0.4
|
L
 -23.1%
H
0.3
1.2
|
L
 -64.9%
H
0.3
1.7
|
L
 -95.2%
H
0.3
17.8
|
L
 -99.3%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
42.0
|
3.6
|
L
 5.6%
H
3.4
3.6
|
L
 9.2%
H
3.0
3.6
|
L
 -12.0%
H
3.0
4.4
|
L
 21.0%
H
2.7
5.8
|
L
 169.2%
H
1.1
9.1
|
L
 -86.7%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
14.2
|
0.7
|
L
 5.7%
H
0.7
0.8
|
L
 32.1%
H
0.5
0.8
|
L
 -28.2%
H
0.5
1.1
|
L
 -31.5%
H
0.5
1.3
|
L
 -8.6%
H
0.5
2.1
|
L
 -63.9%
H
0.5
4.3
|
L
 -98.2%
H
0.5
55
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
44.7
|
0.9
|
L
H
0.9
0.9
|
L
 -6.1%
H
0.8
1.0
|
L
 18.0%
H
0.8
1.1
|
L
 67.3%
H
0.5
1.1
|
L
 7.0%
H
0.5
2.4
|
L
 -64.2%
H
0.5
8.2
|
L
H
0.5
24.0
|
L
H
0.5
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,692.6
|
29.3
|
L
 0.1%
H
29.0
29.5
|
L
 2.7%
H
28.1
29.9
|
L
 5.9%
H
26.3
29.9
|
L
 -19.7%
H
25.9
38.4
|
L
 1.7%
H
25.5
40.9
|
L
 -7.2%
H
18.6
41.6
|
L
 3.4%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,510.8
|
40.6
|
L
 4.6%
H
39.8
41.4
|
L
 10.5%
H
35.5
41.4
|
L
 19%
H
33.0
41.4
|
L
 -16.3%
H
33.0
54.5
|
L
 70.6%
H
21.2
54.9
|
L
 85.0%
H
7.6
59.2
|
L
 455.9%
H
5.4
59.2
|
L
 935.2%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
179.1
|
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 14.5%
H
0.8
1.0
|
L
 8.0%
H
0.7
1.0
|
L
 -36.2%
H
0.7
1.5
|
L
 -50.5%
H
0.7
2.6
|
L
 -65.2%
H
0.5
3.9
|
L
 -94.6%
H
0.5
19.0
|
L
 -95.5%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
18.2
|
3.1
|
L
 1.6%
H
3.1
3.3
|
L
 -15.2%
H
2.8
3.8
|
L
 25.8%
H
2.2
6.5
|
L
 -55.2%
H
2.1
7.3
|
L
 -50.5%
H
2.1
38.3
|
L
 -97.4%
H
2.1
123.3
|
L
 -97.0%
H
2.1
146.3
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
153.2
|
0.7
|
L
 -6.8%
H
0.7
0.8
|
L
 6.2%
H
0.6
0.8
|
L
 -40.5%
H
0.6
1.2
|
L
 -37.3%
H
0.6
1.3
|
L
 -55.2%
H
0.6
2.9
|
L
 -78.8%
H
0.6
10.0
|
L
 -93.6%
H
0.6
17.5
|
L
H
0.6
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
2,646.3
|
15.4
|
L
 0.6%
H
15.3
15.5
|
L
 2.7%
H
15.0
15.6
|
L
 10.1%
H
13.7
15.7
|
L
 0.5%
H
13.1
16.3
|
L
 7.0%
H
13.0
19.5
|
L
 -13.2%
H
10.7
21.9
|
L
 -47.6%
H
7.4
43.9
|
L
 14.2%
H
7.4
43.9
|
| ImmunityBio Inc |
|
7,528.5
|
7.3
|
L
 -6.3%
H
7.1
7.9
|
L
 4.4%
H
7.0
7.9
|
L
 -13.1%
H
6.5
9.5
|
L
 84.6%
H
4.4
12.4
|
L
 162.2%
H
1.8
12.4
|
L
 277.7%
H
1.3
12.4
|
L
 -57.8%
H
1.2
19.7
|
L
H
1.2
40.8
|
| Immucell Corp |
|
68.1
|
7.5
|
L
 -0.9%
H
7.5
7.7
|
L
 18.0%
H
6.8
7.8
|
L
 18.2%
H
6
7.8
|
L
 13.4%
H
5.8
7.8
|
L
 39.7%
H
4.5
7.8
|
L
 53.4%
H
3.3
7.8
|
L
 -18.9%
H
3.3
11.1
|
L
 13.7%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
2,836.4
|
32.3
|
L
 0.4%
H
32
32.7
|
L
 4.3%
H
30.2
38.1
|
L
 -2.4%
H
29.6
38.1
|
L
 -10.4%
H
29.5
38.1
|
L
 90.2%
H
15.8
39.3
|
L
 134.1%
H
13.5
47.7
|
L
 72.7%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
86.8
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 26.3%
H
1.0
1.3
|
L
 26.3%
H
0.8
1.3
|
L
 20%
H
0.8
1.3
|
L
 9.1%
H
0.7
1.9
|
L
 -72.3%
H
0.7
5.2
|
L
 -67.6%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
64.1
|
5.7
|
L
 1.4%
H
5.5
5.8
|
L
 25.4%
H
4.5
6.6
|
L
 -3.1%
H
3.9
6.6
|
L
 -12.9%
H
3.9
7.6
|
L
 -58.1%
H
3.9
18
|
L
 -90.5%
H
3.9
91.7
|
L
 -97.4%
H
3.9
317.9
|
L
H
3.9
451.3
|
| Inhibikase Therapeutics Inc |
|
220.5
|
1.7
|
L
 -6.7%
H
1.7
1.8
|
L
 -4.0%
H
1.7
1.8
|
L
 -16.5%
H
1.6
2.1
|
L
 1.2%
H
1.5
2.3
|
L
 -12.1%
H
1.3
2.4
|
L
 -51.7%
H
0.8
4.4
|
L
 -94.9%
H
0.8
38.5
|
L
H
0.8
70.8
|
| Illumina Inc |
|
19,949.9
|
131.3
|
L
 -0.7%
H
128.3
132.3
|
L
 2.6%
H
118.3
133.4
|
L
 10.4%
H
116.7
133.4
|
L
 -9.6%
H
112.7
155.5
|
L
 76.1%
H
69.9
155.5
|
L
 -42.4%
H
68.7
232.2
|
L
 -67.3%
H
68.7
526
|
L
 -24.4%
H
68.7
555.8
|
| IM Cannabis Corp |
|
2.3
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 8.8%
H
0.3
0.4
|
L
 -58.9%
H
0.3
0.9
|
L
 -72.6%
H
0.3
1.5
|
L
 -74.7%
H
0.3
7.1
|
L
 -91.3%
H
0.3
8.6
|
L
 -99.9%
H
0.3
420
|
L
H
0.3
697.8
|
| Immix Biopharma Inc |
|
532.8
|
10.1
|
L
 0.1%
H
9.3
10.1
|
L
 14.9%
H
8.7
10.2
|
L
 0.5%
H
8
11.6
|
L
 113.4%
H
4.5
11.6
|
L
 498.2%
H
1.6
11.6
|
L
 458.3%
H
1.3
11.6
|
L
H
0.7
11.6
|
L
H
0.7
11.6
|
| Immunome Inc |
|
2,648.4
|
23.4
|
L
 0.1%
H
22.9
23.5
|
L
 7.9%
H
21.4
23.7
|
L
 15.0%
H
19.2
23.7
|
L
 2.5%
H
19.2
27.7
|
L
 216.4%
H
7.0
27.7
|
L
 385.7%
H
4.4
31.0
|
L
 -11.0%
H
2.1
32.5
|
L
H
2.1
63.8
|
| Imunon Inc |
|
12.1
|
3.1
|
L
 -2.2%
H
3
3.2
|
L
 -1.6%
H
2.9
3.2
|
L
 3.0%
H
2.5
3.2
|
L
 -11.2%
H
2.5
3.9
|
L
 -76.6%
H
2.5
47.4
|
L
 -81.7%
H
2.5
54.8
|
L
 -98.8%
H
2.5
348.8
|
L
 -99.9%
H
2.5
5607
|
| Immuneering Corp (Class A) |
|
360.1
|
5.6
|
L
 -3.1%
H
5.5
5.8
|
L
 1.3%
H
5.3
5.9
|
L
 10.3%
H
4.7
5.9
|
L
 20.0%
H
4.4
5.9
|
L
 331.8%
H
1.1
10.1
|
L
 -55.7%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,452.3
|
10.8
|
L
 -1.6%
H
10.6
11.0
|
L
 2.9%
H
10.4
11.1
|
L
 17.2%
H
9.1
11.1
|
L
 9.2%
H
8.6
11.1
|
L
 147.8%
H
3.9
12.4
|
L
 73.8%
H
3.3
13.8
|
L
 -14.5%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
133.1
|
1.0
|
L
 -8.1%
H
1.0
1.1
|
L
 -14.3%
H
1.0
1.3
|
L
 -12.8%
H
1.0
1.4
|
L
 59.4%
H
0.6
1.5
|
L
 3.0%
H
0.5
1.5
|
L
 -28.7%
H
0.5
3.1
|
L
 -93.4%
H
0.5
15.7
|
L
 -99.7%
H
0.5
390
|
| Immunovant Inc |
|
5,574.7
|
27.4
|
L
 -0.2%
H
26.8
27.9
|
L
 10.8%
H
24.4
27.9
|
L
 12.2%
H
22.8
27.9
|
L
 5.4%
H
22.8
29.3
|
L
 77.2%
H
13.4
29.3
|
L
 91.9%
H
12.7
45.6
|
L
 72.5%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
14.2
|
1.4
|
L
 2.9%
H
1.4
1.5
|
L
 -0.7%
H
1.3
1.5
|
L
 -23.8%
H
1.3
2.1
|
L
 -37.9%
H
1.3
2.7
|
L
 800%
H
0.1
4.2
|
L
 19.0%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,894.0
|
82.2
|
L
 -1.7%
H
80.8
83.7
|
L
 22.4%
H
66.4
85.9
|
L
 19.6%
H
57.3
85.9
|
L
 14.5%
H
57.3
88.7
|
L
 597.1%
H
10.8
94.6
|
L
 350.4%
H
10.8
94.6
|
L
 291.8%
H
7.7
94.6
|
L
H
7.7
94.6
|
| Incyte |
|
18,878.5
|
94.9
|
L
 -2.3%
H
94.6
97.5
|
L
 -1.1%
H
93.8
99.9
|
L
 2.5%
H
89.3
99.9
|
L
 -9.9%
H
89.3
109.5
|
L
 62.3%
H
56.1
112.3
|
L
 27.3%
H
50.3
112.3
|
L
 14.0%
H
50.3
112.3
|
L
 22.0%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
6.8
|
3.0
|
L
 11.4%
H
2.6
3.1
|
L
 92.4%
H
1.5
3.1
|
L
 70.6%
H
1.5
3.1
|
L
H
1.5
3.7
|
L
 504%
H
0.3
13.4
|
L
 54.9%
H
0.3
13.4
|
L
 -80.9%
H
0.3
28.8
|
L
 -99.0%
H
0.3
8800
|
| Indivior PLC |
|
3,864.9
|
31.7
|
L
 -2.5%
H
31.2
32.8
|
L
 -0.8%
H
30.1
33.6
|
L
 1.9%
H
27.7
33.6
|
L
 -3.6%
H
27.7
36.0
|
L
 248.0%
H
8.7
38
|
L
 81.7%
H
7.3
38
|
L
 1641.8%
H
1.8
38
|
L
 1278.3%
H
0.4
38
|
| MiNK Therapeutics Inc |
|
69.8
|
14.1
|
L
 8.6%
H
12.9
14.2
|
L
 26.0%
H
10.9
14.2
|
L
 44.3%
H
8.5
14.2
|
L
 18.8%
H
8.5
16.9
|
L
 81.3%
H
6.3
76
|
L
 -36.4%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
2.3
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 7.7%
H
0.6
0.7
|
L
 -9.1%
H
0.6
0.9
|
L
 -34.6%
H
0.6
1.2
|
L
 -74.8%
H
0.6
8.0
|
L
 -97.2%
H
0.6
41.6
|
L
 -100.0%
H
0.6
1930
|
L
 -100.0%
H
0.6
32175
|
| INmune Bio Inc |
|
35.4
|
1.3
|
L
 0.8%
H
1.3
1.4
|
L
 3.1%
H
1.2
1.4
|
L
 1.5%
H
1.1
1.4
|
L
 -18.4%
H
1.1
1.8
|
L
 -82.2%
H
1.1
11.6
|
L
 -84.7%
H
1.1
14.7
|
L
 -87.7%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Inovio Pharma Inc |
|
94.6
|
1.2
|
L
 -2.5%
H
1.1
1.2
|
L
 6.4%
H
1.0
1.2
|
L
 -30.1%
H
1.0
1.8
|
L
 -26.6%
H
1.0
2.0
|
L
 -34.1%
H
1.0
3.0
|
L
 36.5%
H
0.3
14.8
|
L
 -87.1%
H
0.3
14.8
|
L
 -87.8%
H
0.3
33.8
|
| Insmed Inc |
|
30,817.2
|
142.8
|
L
 -2.7%
H
142.0
146.2
|
L
 -10.9%
H
142.0
160.5
|
L
 2.3%
H
135.7
166.2
|
L
 -10.4%
H
135.7
167.4
|
L
 100.9%
H
63.8
212.8
|
L
 752.4%
H
16.8
212.8
|
L
 324.7%
H
16.0
212.8
|
L
 984.9%
H
9.0
212.8
|
| Innoviva Inc |
|
1,733.5
|
23.4
|
L
 -2.1%
H
23.3
24.0
|
L
 -0.9%
H
23.3
24.4
|
L
 6.3%
H
21.6
24.4
|
L
 18.5%
H
19.3
25.1
|
L
 29.3%
H
16.5
25.1
|
L
 94.8%
H
11.2
25.1
|
L
 96.9%
H
10.6
25.1
|
L
 74.7%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
12,363.0
|
74.8
|
L
 -2.6%
H
73.9
76.5
|
L
 -0.2%
H
73.9
77.4
|
L
 5.1%
H
68.9
77.4
|
L
 -3.1%
H
68.9
86.7
|
L
 163.7%
H
27.6
86.7
|
L
 102.3%
H
24.0
86.7
|
L
 82.4%
H
24.0
86.7
|
L
 76.2%
H
19.6
86.7
|
| Iovance Biotherapeutics Inc |
|
1,561.3
|
3.8
|
L
 -0.8%
H
3.7
3.9
|
L
 9.2%
H
3.4
4.3
|
L
 -4.3%
H
3.2
4.3
|
L
 70.7%
H
2.2
5.6
|
L
 17.3%
H
1.6
5.6
|
L
 -32.8%
H
1.6
18.3
|
L
 -87.5%
H
1.6
33.6
|
L
 -34.4%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
443.9
|
2.5
|
L
 -4.6%
H
2.4
2.6
|
L
 7.9%
H
2.2
2.6
|
L
 5.6%
H
1.9
2.7
|
L
 7.4%
H
1.7
3.0
|
L
 394%
H
0.4
3.0
|
L
 -20.6%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,646.0
|
69.3
|
L
 -1.2%
H
68.8
70.1
|
L
 4.6%
H
65.5
71.0
|
L
 15.5%
H
57.7
71.0
|
L
 -2.4%
H
40
83.9
|
L
 67.9%
H
39.2
99.5
|
L
 215.9%
H
21.7
99.5
|
L
 -37.0%
H
11.6
129.5
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
710.9
|
4.4
|
L
 -0.2%
H
4.2
4.5
|
L
 24.2%
H
3.4
4.5
|
L
 29.4%
H
3.0
4.5
|
L
 -3.5%
H
3.0
5.6
|
L
 505.6%
H
0.5
5.8
|
L
 -60.3%
H
0.5
15.7
|
L
 -59.8%
H
0.5
15.7
|
L
 -53.8%
H
0.5
17.7
|
| Invivyd Inc |
|
480.8
|
1.7
|
L
 -0.6%
H
1.7
1.7
|
L
 25.9%
H
1.4
1.8
|
L
 -2.3%
H
1.2
1.9
|
L
 -30.3%
H
1.2
2.5
|
L
 233.3%
H
0.5
3.1
|
L
 45.3%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
299.7
|
2.6
|
L
 2.4%
H
2.5
2.6
|
L
 6.1%
H
2.3
2.6
|
L
 -8.1%
H
2.1
3.1
|
L
 -29.0%
H
2.1
4.1
|
L
 185.7%
H
0.8
6.8
|
L
 -26.1%
H
0.6
6.8
|
L
 -95.4%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,583.2
|
31.2
|
L
 -1.3%
H
30.8
31.5
|
L
 -2.0%
H
30.8
32.8
|
L
 1.2%
H
28.9
32.8
|
L
 -4.6%
H
28.9
36.0
|
L
 14.4%
H
26.4
40.7
|
L
 -43.0%
H
23.2
77.0
|
L
 -20.7%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
85.5
|
0.6
|
L
 7.4%
H
0.5
0.7
|
L
 65.7%
H
0.3
1.1
|
L
 20.8%
H
0.3
1.1
|
L
 -80.9%
H
0.3
3.2
|
L
 -61.6%
H
0.3
3.5
|
L
 -63.5%
H
0.3
3.9
|
L
 -82.8%
H
0.3
5.4
|
L
 -81.0%
H
0.3
8.0
|
| Immuron Ltd (ADR) |
|
6.9
|
0.8
|
L
 2.4%
H
0.8
0.9
|
L
 5%
H
0.8
0.9
|
L
 7.7%
H
0.7
0.9
|
L
 -21.5%
H
0.7
1.1
|
L
 -51.5%
H
0.7
2.4
|
L
 -60%
H
0.7
6.0
|
L
 -85.0%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
152.0
|
1.6
|
L
 -4.1%
H
1.6
1.7
|
L
 11.7%
H
1.4
1.8
|
L
 8%
H
1.2
1.8
|
L
 -8.0%
H
1.2
1.9
|
L
 -15.2%
H
1.2
2.6
|
L
 -51.2%
H
1.2
3.6
|
L
 -63.2%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Inventiva (ADR) |
|
1,183.6
|
5.7
|
L
 -0.7%
H
5.5
5.7
|
L
 7.6%
H
4.9
5.8
|
L
 -4.8%
H
4.9
6.3
|
L
 -6.9%
H
4.9
7.3
|
L
 67.7%
H
2.9
8.0
|
L
 87.5%
H
1.5
8.0
|
L
 -57.5%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
5.3
|
0.4
|
L
 -4.7%
H
0.4
0.4
|
L
 2.5%
H
0.3
0.4
|
L
 -18%
H
0.3
0.5
|
L
 -46.1%
H
0.3
1.9
|
L
 -92.0%
H
0.3
15.5
|
L
 -98.8%
H
0.3
73.2
|
L
 -100.0%
H
0.3
30780
|
L
 -100.0%
H
0.3
999999
|
| Janux Therapeutics Inc |
|
921.0
|
15.1
|
L
 0.7%
H
14.9
15.2
|
L
 4.2%
H
14.4
15.5
|
L
 11.5%
H
13.0
15.5
|
L
 10.4%
H
12.1
15.5
|
L
 -47.9%
H
12.1
35.3
|
L
 3.4%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
12,186.5
|
198.0
|
L
 -0.7%
H
197.3
200
|
L
 1.0%
H
192.3
202.6
|
L
 10.9%
H
178.3
202.6
|
L
 15.7%
H
161.4
202.6
|
L
 92.4%
H
97.5
202.6
|
L
 36.0%
H
95.5
202.6
|
L
 17.6%
H
95.5
202.6
|
L
 36.7%
H
86.9
202.6
|
| Jasper Therapeutics Inc |
|
27.2
|
1.0
|
L
 -7.6%
H
1.0
1.1
|
L
 36.6%
H
0.7
1.1
|
L
 -20.5%
H
0.6
1.3
|
L
 -36.2%
H
0.6
1.7
|
L
 -77.1%
H
0.6
7.2
|
L
 -33.1%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kala Pharma Inc |
|
173.2
|
0.2
|
L
 -5%
H
0.2
0.2
|
L
 5.6%
H
0.2
0.2
|
L
 -32.1%
H
0.2
0.3
|
L
 -68.3%
H
0.2
0.7
|
L
 -94.6%
H
0.2
20.6
|
L
 -98.9%
H
0.2
20.6
|
L
 -100.0%
H
0.2
419.2
|
L
H
0.2
1337.5
|
| KalVista Pharma Inc |
|
999.9
|
19.5
|
L
 -6.4%
H
19.3
21.0
|
L
 1.3%
H
19.1
21.0
|
L
 15.2%
H
15.1
21.3
|
L
 30.5%
H
14.2
21.3
|
L
 62.4%
H
9.8
21.3
|
L
 146.8%
H
7.2
21.3
|
L
 -22.5%
H
4.1
30.7
|
L
 119.6%
H
4.1
45
|
| Kamada Ltd |
|
473.6
|
8.2
|
L
 -2.7%
H
8.2
8.4
|
L
 -3.1%
H
8.2
8.6
|
L
 -5.6%
H
8.0
9.1
|
L
 -0.1%
H
7.7
9.4
|
L
 30.5%
H
6.3
9.4
|
L
 78.9%
H
4.1
9.4
|
L
 29.7%
H
3.7
9.4
|
L
 111.6%
H
3.6
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
3,470.9
|
45.4
|
L
 -1.2%
H
44.9
46.6
|
L
 -3.6%
H
44.4
48.5
|
L
 -0.9%
H
44.4
50.0
|
L
 19.6%
H
38.0
50.0
|
L
 113.7%
H
19.6
50.0
|
L
 299.6%
H
10.6
50.0
|
L
 175.9%
H
7.4
50.0
|
L
H
5.0
50.0
|
| Kodiak Sciences Inc |
|
2,476.4
|
40.0
|
L
 -4.6%
H
39.4
42.6
|
L
 -4.2%
H
39.4
46.7
|
L
 72.7%
H
21
46.7
|
L
 50.0%
H
20.9
46.7
|
L
 1633.3%
H
2.2
46.7
|
L
 700.8%
H
1.4
46.7
|
L
 -65.4%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
10.7
|
2.4
|
L
 -4.3%
H
2.4
2.6
|
L
 -15.0%
H
2.4
2.8
|
L
 16.3%
H
1.8
2.9
|
L
 11.0%
H
1.8
2.9
|
L
 -12.9%
H
1.8
4.2
|
L
 -41.4%
H
0.4
5.6
|
L
 -98.6%
H
0.4
257.2
|
L
 -99.9%
H
0.4
2400
|
| Karyopharm Therapeutics Inc |
|
195.2
|
8.7
|
L
 1.2%
H
8.4
8.9
|
L
 19.5%
H
7.2
8.9
|
L
 10.3%
H
5
9.0
|
L
 30.0%
H
5
11.0
|
L
 103.3%
H
3.7
11.0
|
L
 -86.6%
H
0.6
73.1
|
L
 -94.0%
H
0.6
221.0
|
L
 -93.6%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
230.1
|
11.7
|
L
 -0.3%
H
11.6
11.8
|
L
 -7.0%
H
10.8
12.6
|
L
 5.9%
H
10.4
12.6
|
L
 -39.4%
H
10.4
19.9
|
L
 -10.9%
H
10.4
22.6
|
L
 -69.9%
H
9.1
73
|
L
 -81.6%
H
9.1
73
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
7,714.8
|
262.1
|
L
 -2.4%
H
262.0
267.4
|
L
 -0.8%
H
252.3
275.8
|
L
 6%
H
242
275.8
|
L
 -7.1%
H
242
298.3
|
L
 55.0%
H
122.8
298.3
|
L
 203.4%
H
82.1
298.3
|
L
 242.2%
H
38.9
298.3
|
L
H
8.0
298.3
|
| TuHURA Biosciences Inc |
|
186.9
|
2.9
|
L
 -4.2%
H
2.9
3.2
|
L
 62.4%
H
1.7
3.4
|
L
 54.7%
H
1.3
3.4
|
L
 286.8%
H
0.4
3.4
|
L
 -28.3%
H
0.4
4.4
|
L
 -97.0%
H
0.2
209.3
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Pasithea Therapeutics Corp |
|
18.5
|
0.7
|
L
 -1.3%
H
0.7
0.8
|
L
 -3.9%
H
0.7
0.8
|
L
 -9.8%
H
0.5
0.9
|
L
 -16.9%
H
0.5
0.9
|
L
 -43.9%
H
0.3
3.8
|
L
 89.7%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
785.5
|
8.9
|
L
 -2.2%
H
8.8
9.1
|
L
 0.7%
H
8.6
9.3
|
L
 2.3%
H
7.5
9.3
|
L
 -0.7%
H
7.4
9.6
|
L
 46.8%
H
5.5
12.5
|
L
 -22.6%
H
5.4
24.2
|
L
 -70.0%
H
5.4
29.9
|
L
 162.6%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
6,959.2
|
85.2
|
L
 -4.2%
H
84.6
89.2
|
L
 -2.2%
H
84.2
90.1
|
L
 7.9%
H
73.3
90.1
|
L
 19.9%
H
66.2
95.9
|
L
 234.8%
H
24.4
103
|
L
 159.4%
H
9.6
103
|
L
 121.1%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
54.3
|
7.4
|
L
 -0.3%
H
7.4
7.5
|
L
 -0.3%
H
7.3
7.5
|
L
 7.5%
H
6.1
7.6
|
L
 18.7%
H
6.0
7.6
|
L
 79.1%
H
3.5
7.6
|
L
 -69.1%
H
0.7
31.3
|
L
 -87.6%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Kazia Therapeutics Ltd (ADR) |
|
122.3
|
10.7
|
L
 7%
H
9.5
10.8
|
L
 17.6%
H
8.4
11
|
L
 42.9%
H
6.8
11
|
L
 52.6%
H
4.9
11
|
L
 194.8%
H
2.9
17.4
|
L
 -83.8%
H
2.9
84
|
L
 -98.1%
H
2.9
614
|
L
 -97.9%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
24.0
|
1.0
|
L
 -5.8%
H
1.0
1.0
|
L
 1.0%
H
0.9
1.1
|
L
 38.6%
H
0.7
1.1
|
L
 32.9%
H
0.6
1.1
|
L
 -32.2%
H
0.5
1.7
|
L
 -55.5%
H
0.5
6.9
|
L
 -80.9%
H
0.5
12.5
|
L
 -65.4%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
195.3
|
5.2
|
L
 -3.2%
H
5.2
5.4
|
L
 22.9%
H
4.1
5.5
|
L
 -20.3%
H
3.6
6.5
|
L
 -35.7%
H
3.6
9.0
|
L
 -16.6%
H
3.6
9.0
|
L
 36.0%
H
3.6
11.5
|
L
 -53.9%
H
1.5
12.9
|
L
 -50.4%
H
1.5
15.6
|
| Lifevantage Corp |
|
57.6
|
4.5
|
L
 3.5%
H
4.4
4.5
|
L
 10.6%
H
3.9
4.5
|
L
 -13.3%
H
3.9
5.3
|
L
 -28.9%
H
3.9
6.5
|
L
 -68.9%
H
3.9
15
|
L
 33.9%
H
3.0
27.4
|
L
 -49.0%
H
3.0
27.4
|
L
 -45.2%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
4,453.9
|
223.4
|
L
 -0.8%
H
218.2
226.0
|
L
 7.3%
H
198.6
234.8
|
L
 10.1%
H
188.7
234.8
|
L
 13.9%
H
178.7
234.8
|
L
 109.1%
H
98.9
234.8
|
L
 200.4%
H
49.3
234.8
|
L
 132.5%
H
46.8
234.8
|
L
 177.8%
H
36.9
234.8
|
| Longeveron Inc (Class A) |
|
31.6
|
1.1
|
L
 -3.6%
H
1.1
1.1
|
L
 -4.4%
H
1.1
1.2
|
L
 11.3%
H
0.8
1.2
|
L
 92.9%
H
0.5
1.2
|
L
 -26.0%
H
0.5
1.8
|
L
 -96.1%
H
0.5
44
|
L
 -98.5%
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
81.4
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 3.8%
H
0.8
0.9
|
L
 -2.4%
H
0.7
0.9
|
L
 16.9%
H
0.7
1.1
|
L
 -72.2%
H
0.6
7.3
|
L
 -56.5%
H
0.6
7.3
|
L
 -77.6%
H
0.6
13.1
|
L
 -98.6%
H
0.6
90.9
|
| Lixte biotech Holdings Inc |
|
36.7
|
3.2
|
L
 1.6%
H
3.1
3.2
|
L
 10.9%
H
2.7
3.2
|
L
 1.6%
H
2.5
3.2
|
L
 -7.3%
H
2.4
4.0
|
L
 154.8%
H
0.6
6.3
|
L
 -49.8%
H
0.6
9.5
|
L
 -89.0%
H
0.6
49.5
|
L
 -62.4%
H
0.6
110.4
|
| Lipocine Inc |
|
18.4
|
2.5
|
L
 -1.6%
H
2.4
2.6
|
L
 18.3%
H
2.0
2.6
|
L
 -65.7%
H
1.8
9.3
|
L
 -77.6%
H
1.8
11.4
|
L
 -17.4%
H
1.8
12.4
|
L
 -48.0%
H
1.8
12.4
|
L
 -89.6%
H
1.8
32.1
|
L
 -98.8%
H
1.8
204.2
|
| Leap Therapeutics Inc |
|
79.2
|
0.9
|
L
 -2.2%
H
0.8
0.9
|
L
 8.6%
H
0.8
1.1
|
L
 51.7%
H
0.6
1.1
|
L
 -20%
H
0.5
1.1
|
L
 137.8%
H
0.2
3.7
|
L
 -77.6%
H
0.2
10.2
|
L
 -94.8%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
3,691.1
|
41.9
|
L
 4.4%
H
39.5
42.0
|
L
 9.7%
H
37.6
42.0
|
L
 14.3%
H
34.2
42.0
|
L
 8.0%
H
29.1
46.7
|
L
 208.0%
H
11.9
46.7
|
L
 519.7%
H
5.7
46.7
|
L
 1428.8%
H
2.3
46.7
|
L
H
2.3
46.7
|
| Larimar Therapeutics Inc |
|
495.5
|
4.8
|
L
 -1.2%
H
4.7
4.8
|
L
 -6.3%
H
4.7
5.2
|
L
 3.7%
H
4.2
5.4
|
L
 46.3%
H
2.7
6.4
|
L
 153.7%
H
1.7
6.4
|
L
 5.3%
H
1.6
13.7
|
L
 -58.2%
H
1.5
15.5
|
L
 -94.3%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
29.9
|
3.3
|
L
 -17.5%
H
3.3
3.8
|
L
 -33.8%
H
3.3
5.0
|
L
 -34.2%
H
3.3
5.1
|
L
 51.8%
H
2.1
5.1
|
L
 52.5%
H
1.8
5.1
|
L
 6.1%
H
1.8
5.1
|
L
 -85.8%
H
1.8
25.7
|
L
 -96.7%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
29.5
|
2.6
|
L
 8.3%
H
2.4
2.8
|
L
 35.1%
H
1.9
2.8
|
L
 9.6%
H
1.1
2.8
|
L
 -25.4%
H
1.1
3.6
|
L
 -25.6%
H
1.1
5.7
|
L
 -47.9%
H
1.1
12.0
|
L
 -83.4%
H
1.1
16.9
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
775.3
|
1.8
|
L
 -1.6%
H
1.8
1.9
|
L
 9.6%
H
1.7
1.9
|
L
 8.3%
H
1.5
1.9
|
L
 43.0%
H
1.1
1.9
|
L
 258.8%
H
0.5
1.9
|
L
 -24.1%
H
0.3
3.8
|
L
 -64.9%
H
0.3
6.3
|
L
 -87.2%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
544.7
|
23.4
|
L
 -2.1%
H
23.3
24.6
|
L
 1.9%
H
22.4
25.3
|
L
 9.9%
H
17.3
25.3
|
L
 1.8%
H
17.3
27.9
|
L
 154.4%
H
7.7
45
|
L
 -50.5%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Legend Biotech Corp (ADR) |
|
3,889.6
|
21.0
|
L
 2.5%
H
20.3
22.0
|
L
 14.9%
H
17.6
22.0
|
L
 12.2%
H
16.7
22.0
|
L
 -4.9%
H
16.2
23.9
|
L
 -37.7%
H
16.2
45.3
|
L
 -60.3%
H
16.2
77.3
|
L
 -18.5%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
5.8
|
0.8
|
L
H
0.8
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 -19.2%
H
0.7
1.0
|
L
 -27.6%
H
0.5
1.1
|
L
 -44.1%
H
0.5
7
|
L
 -99.6%
H
0.1
408.5
|
L
 -100.0%
H
0.1
3045
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
159.2
|
2.4
|
L
 -0.8%
H
2.3
2.4
|
L
 0.9%
H
2.2
2.7
|
L
 -11.9%
H
2.2
2.8
|
L
 13.4%
H
1.6
2.9
|
L
 -7.1%
H
1.6
4.7
|
L
 33.1%
H
0.8
4.7
|
L
 -69.3%
H
0.8
9.6
|
L
 -99.4%
H
0.8
598.4
|
| Moleculin Biotech Inc |
|
12.8
|
2.4
|
L
 -1.6%
H
2.4
2.4
|
L
 -1.2%
H
2.4
2.8
|
L
 17.7%
H
2.0
2.8
|
L
 -43.8%
H
1.8
5.3
|
L
 -88.7%
H
1.8
28.6
|
L
 -99.3%
H
1.8
3318.8
|
L
 -99.8%
H
1.8
3318.8
|
L
H
1.8
21555
|
| Seres Therapeutics Inc |
|
84.3
|
8.8
|
L
 -0.6%
H
8.6
8.9
|
L
 0.3%
H
8.3
9.2
|
L
 1.9%
H
8.1
9.6
|
L
 -42.1%
H
7.9
16.1
|
L
 1810.9%
H
0.4
30.0
|
L
 50%
H
0.4
30.0
|
L
 -58.9%
H
0.4
30.0
|
L
 -70.7%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
12,006.8
|
523.4
|
L
 0.9%
H
510.6
526.9
|
L
 0.7%
H
507.5
539.2
|
L
 17.7%
H
427.8
572.2
|
L
 5.6%
H
416.2
572.2
|
L
 63%
H
265
615
|
L
 118.3%
H
119.8
615
|
L
 313.3%
H
52.3
615
|
L
 3811.8%
H
6.6
615
|
| MediWound Ltd |
|
221.4
|
17.2
|
L
 -0.1%
H
16.9
17.4
|
L
 -0.2%
H
16.9
18.1
|
L
 3.9%
H
14.9
18.1
|
L
 -0.8%
H
14.9
18.7
|
L
 5.4%
H
14.9
22.5
|
L
 32.3%
H
7.1
24
|
L
 -52.1%
H
7.1
43.5
|
L
 -69.4%
H
7.1
62.3
|
| MEI Pharma Inc |
|
42.9
|
1.2
|
L
 -1.7%
H
1.2
1.2
|
L
 3.5%
H
1.1
1.2
|
L
H
1.0
1.3
|
L
 -15.7%
H
1.0
1.4
|
L
 -42.2%
H
1.0
9
|
L
 -75.4%
H
1.0
9
|
L
 -98.3%
H
1.0
78.2
|
L
 -96.3%
H
1.0
102.8
|
| Macrogenics Inc |
|
214.8
|
3.4
|
L
 -4.0%
H
3.4
3.6
|
L
 -2.0%
H
3.3
3.9
|
L
 12.7%
H
2.7
3.9
|
L
 98.8%
H
1.6
3.9
|
L
 168.3%
H
1.1
3.9
|
L
 -47.9%
H
1.0
21.9
|
L
 -89.6%
H
1.0
36.5
|
L
 -84.8%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
8.3
|
0.5
|
L
 22.5%
H
0.4
0.5
|
L
 44.1%
H
0.3
0.5
|
L
 29.0%
H
0.2
0.5
|
L
 -25.8%
H
0.2
0.7
|
L
 -75.5%
H
0.2
2.9
|
L
 -52.4%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
95.8
|
L
 0.9%
H
93.2
96
|
L
 9.5%
H
87.1
96.0
|
L
 23.0%
H
75.5
96.0
|
L
 117.6%
H
42.7
96.0
|
L
 386.3%
H
16.6
96.0
|
L
 667.3%
H
9.1
96.0
|
L
 -44.7%
H
5.1
211.5
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
758.3
|
9.3
|
L
 -17.2%
H
8.8
10.1
|
L
 -0.9%
H
8.8
11.9
|
L
 26.0%
H
7.0
11.9
|
L
 21.1%
H
6.6
11.9
|
L
 70.8%
H
4.6
11.9
|
L
 75.3%
H
3.5
11.9
|
L
 -34.9%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
5,760.8
|
95.5
|
L
 -1.0%
H
94.8
96.5
|
L
 -2.5%
H
92.8
99.2
|
L
 5.3%
H
84.9
99.4
|
L
 3.4%
H
84.3
109.3
|
L
 147.1%
H
37.8
109.3
|
L
 282.0%
H
23.1
109.3
|
L
 421.4%
H
12.8
109.3
|
L
H
6.5
109.3
|
| Milestone Pharma Inc |
|
247.1
|
2.1
|
L
 -4.6%
H
2.1
2.3
|
L
 18.0%
H
1.8
2.3
|
L
 23.5%
H
1
2.3
|
L
 3.5%
H
1
2.3
|
L
 153.0%
H
0.8
3.1
|
L
 -41.5%
H
0.6
4.5
|
L
 -61.2%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,266.0
|
17.7
|
L
 -2.1%
H
17.5
18.2
|
L
 -5.1%
H
17.5
19.7
|
L
 3.0%
H
15.8
19.7
|
L
 8.0%
H
14.5
19.7
|
L
 -52%
H
6.0
62.8
|
L
 -7.3%
H
6.0
65.0
|
L
 73.0%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,509.0
|
30.4
|
L
 0.0%
H
30.1
31.5
|
L
 9.6%
H
26.1
31.5
|
L
 16.2%
H
22.4
31.5
|
L
 -3.0%
H
22.4
34.7
|
L
 119.2%
H
12.6
47.7
|
L
 130.5%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
849.2
|
2.8
|
L
 -0.7%
H
2.7
2.8
|
L
 5.4%
H
2.6
2.8
|
L
 -0.7%
H
2.2
2.9
|
L
 -50.7%
H
2.2
6.3
|
L
 -40.7%
H
2.2
6.5
|
L
 -31.8%
H
2.2
7.6
|
L
 -36.0%
H
2.2
7.6
|
L
 -66.5%
H
0.7
8.8
|
| Mind Medicine Inc |
|
2,235.2
|
22.4
|
L
 1.2%
H
21.6
23.4
|
L
 6.7%
H
20.4
23.4
|
L
 24.1%
H
17.1
23.4
|
L
 45.8%
H
14.6
23.4
|
L
 300.4%
H
5.4
23.4
|
L
 609.5%
H
2.4
23.4
|
L
 -39.0%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
69.9
|
1.4
|
L
 -0.7%
H
1.4
1.5
|
L
 -1.4%
H
1.4
1.5
|
L
 5.2%
H
1.4
1.6
|
L
 -10.1%
H
1.3
1.9
|
L
 1.4%
H
1.2
2.0
|
L
 -38.3%
H
1.1
2.7
|
L
 -69.5%
H
1.1
5.1
|
L
 -84.2%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
383.9
|
57.4
|
L
 -0.9%
H
55.9
58.1
|
L
 -1.1%
H
54.7
60.1
|
L
 -5.0%
H
50.5
64.9
|
L
 -16.9%
H
50.5
76.1
|
L
 49.6%
H
28.4
105
|
L
 809.2%
H
1.4
105
|
L
 122.8%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
27.0
|
1.6
|
L
 2.5%
H
1.6
1.7
|
L
 11.0%
H
1.5
1.8
|
L
 21.8%
H
1.2
1.8
|
L
 -8.0%
H
1.2
2.3
|
L
 38.5%
H
0.8
4.1
|
L
 47.3%
H
0.8
9.7
|
L
 -92.2%
H
0.7
36.5
|
L
 -97.7%
H
0.7
135.5
|
| Moderna |
|
21,697.3
|
54.7
|
L
 0.8%
H
52.8
54.9
|
L
 5.0%
H
50.0
55.2
|
L
 4.1%
H
47.1
56.5
|
L
 39%
H
36.7
59.6
|
L
 108.5%
H
22.3
59.6
|
L
 -65.2%
H
22.3
170.5
|
L
 -65.8%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
496.2
|
3.4
|
L
 -3.1%
H
3.3
3.5
|
L
 9%
H
3.0
3.5
|
L
 10.1%
H
2.8
3.5
|
L
 -8.1%
H
2.8
4
|
L
 96.0%
H
1.7
4.1
|
L
 -76.0%
H
1.7
16.6
|
L
 -90.7%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
10.4
|
5.5
|
L
 10.1%
H
5.1
5.5
|
L
 -18.4%
H
4.7
6.6
|
L
 -17.3%
H
4.7
8.5
|
L
 -40.2%
H
4.7
8.5
|
L
 -49.0%
H
4.7
12.5
|
L
 -64.8%
H
4.7
16.5
|
L
 -72.1%
H
4.7
49.1
|
L
 -73.5%
H
4.7
49.1
|
| MaxCyte Inc |
|
87.6
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 9.3%
H
0.7
0.9
|
L
H
0.7
0.9
|
L
 -36.4%
H
0.6
1.3
|
L
 -69.1%
H
0.6
3.0
|
L
 -84.7%
H
0.6
5.5
|
L
 -86.0%
H
0.6
17.4
|
L
H
0.6
17.4
|
| TNF Pharma Inc |
|
29.8
|
3.8
|
L
 -6.6%
H
3.7
4.2
|
L
 5.3%
H
3.5
4.2
|
L
 -1.3%
H
3.1
4.6
|
L
 -22.8%
H
3.1
6.3
|
L
 -85.9%
H
2.5
33.6
|
L
 -99.9%
H
2.5
7050
|
L
 -100.0%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
6.5
|
0.5
|
L
 -5.5%
H
0.5
0.6
|
L
 2.0%
H
0.4
0.6
|
L
 -29.7%
H
0.4
0.7
|
L
 -56.3%
H
0.4
1.6
|
L
 -84.4%
H
0.4
4.4
|
L
 -99.8%
H
0.4
242.4
|
L
H
0.4
1200
|
L
H
0.4
1200
|
| Mesoblast Ltd (ADR) |
|
2,073.2
|
16.1
|
L
 2.2%
H
15.9
16.3
|
L
 15.6%
H
14.1
16.3
|
L
 10.6%
H
13.3
16.5
|
L
 -9.3%
H
13.3
19.3
|
L
 49.4%
H
9.9
21.5
|
L
 367.7%
H
1.0
22
|
L
 78.8%
H
1.0
22
|
L
 72.1%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
156.4
|
4.2
|
L
 -0.5%
H
4.2
4.2
|
L
 -1.4%
H
4
4.3
|
L
 -1.0%
H
3.7
5.0
|
L
 -2.3%
H
3.7
5.4
|
L
 6.9%
H
3.4
5.4
|
L
 -36.0%
H
3.3
12.7
|
L
 -82.7%
H
3.3
32.0
|
L
 -84.4%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
51.1
|
0.3
|
L
 -5.9%
H
0.3
0.4
|
L
H
0.3
0.4
|
L
 -18.0%
H
0.3
0.4
|
L
 -52.2%
H
0.3
0.7
|
L
 -84%
H
0.2
3.1
|
L
 -69.5%
H
0.2
5.0
|
L
 -90.4%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
16.3
|
2.6
|
L
 -1.9%
H
2.6
2.7
|
L
 -5.7%
H
2.6
2.9
|
L
 -2.2%
H
2.5
3.3
|
L
 -43.1%
H
2.3
4.8
|
L
 -6.4%
H
2.3
5.0
|
L
 -69.8%
H
2.3
9.4
|
L
 -84.5%
H
2.3
19.9
|
L
 -80.2%
H
2.3
19.9
|
| NewAmsterdam Pharma Co NV |
|
3,857.4
|
33.6
|
L
 -1.4%
H
32.9
34.3
|
L
 -1.4%
H
32.9
36.7
|
L
 17.2%
H
28.7
36.7
|
L
 5.4%
H
28.5
37.8
|
L
 108.9%
H
15.7
42
|
L
 150.4%
H
5.6
42
|
L
 237.9%
H
5.6
42
|
L
H
5.6
42
|
| Nature`s Sunshine Products Inc |
|
459.0
|
26.2
|
L
 -0.7%
H
25.9
26.5
|
L
 -0.8%
H
25.9
27.2
|
L
 7.1%
H
22.7
27.2
|
L
 15.8%
H
22.2
28.1
|
L
 117.4%
H
11.2
28.1
|
L
 154.8%
H
9.9
28.1
|
L
 29.1%
H
7.9
28.1
|
L
 169.2%
H
5.5
28.1
|
| Nautilus biotech Inc |
|
387.3
|
3.1
|
L
 -5.9%
H
2.9
3.3
|
L
 -2.2%
H
2.8
3.3
|
L
 31.3%
H
2.3
4.3
|
L
 67.2%
H
1.8
4.3
|
L
 297.4%
H
0.6
4.3
|
L
 8.1%
H
0.6
4.7
|
L
 -74.7%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
12,839.5
|
127.9
|
L
 -2.7%
H
127.8
131.7
|
L
 -3.9%
H
125.6
133.2
|
L
 -1.4%
H
125.1
134.2
|
L
 -4.1%
H
122.1
142.8
|
L
 33.0%
H
97.3
160.2
|
L
 24.5%
H
84.2
160.2
|
L
 34.7%
H
71.9
160.2
|
L
 174.9%
H
37.3
160.2
|
| Minerva Neurosciences Inc |
|
273.1
|
6.3
|
L
 2.1%
H
6.0
6.5
|
L
 16.4%
H
5.1
6.7
|
L
 -19.4%
H
5.0
8.8
|
L
 45.7%
H
3.8
8.8
|
L
 326.4%
H
1.3
12.5
|
L
 176.8%
H
1.2
13.5
|
L
 -68.6%
H
1.2
28.3
|
L
 -87.5%
H
1.2
126.7
|
| Nektar Therapeutics |
|
2,396.6
|
83.5
|
L
 0.4%
H
80.5
84.4
|
L
 11.3%
H
74.8
84.4
|
L
 14.1%
H
64.1
84.4
|
L
 136.3%
H
33.4
84.4
|
L
 772.9%
H
8.0
84.4
|
L
 498.9%
H
6.2
84.4
|
L
 -71.2%
H
6.2
309.9
|
L
 -63.2%
H
6.2
1670.4
|
| Nkarta Inc |
|
196.0
|
2.8
|
L
 13.6%
H
2.5
2.8
|
L
 19.1%
H
2.1
2.8
|
L
 21.7%
H
2.0
2.8
|
L
 40.3%
H
1.9
2.8
|
L
 60.8%
H
1.6
2.8
|
L
 -39.2%
H
1.3
16.2
|
L
 -92.5%
H
1.3
40.6
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
11.5
|
2.5
|
L
 0.8%
H
2.5
2.6
|
L
 18.3%
H
2.1
2.7
|
L
 -8.0%
H
1.8
2.8
|
L
 3.3%
H
1.8
3.3
|
L
 -83.2%
H
1.8
30.8
|
L
 -99.6%
H
1.2
632
|
L
 -99.8%
H
1.2
1556
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
24
|
L
 15.6%
H
20.9
24.9
|
L
 11.1%
H
19.1
24.9
|
L
 11.6%
H
18.2
24.9
|
L
 32.9%
H
15.9
26.4
|
L
 33.4%
H
14.7
37.3
|
L
 51.9%
H
12.2
37.3
|
L
 -90.2%
H
7.5
268
|
L
 -87.6%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
7.8
|
L
 0.5%
H
7.7
7.8
|
L
 1.8%
H
7.5
7.8
|
L
 -1.4%
H
7.0
8.0
|
L
 -8.2%
H
7.0
8.8
|
L
 9.0%
H
6.2
8.8
|
L
 479.1%
H
0.0
8.8
|
L
 -65.4%
H
0.0
31
|
L
H
0.0
1010
|
| MetaVia Inc |
|
7.2
|
1.4
|
L
 -0.7%
H
1.4
1.4
|
L
 14.6%
H
1.2
1.6
|
L
 -12.4%
H
1.2
1.6
|
L
 -57.3%
H
1.2
3.4
|
L
 -84.2%
H
1.2
19.0
|
L
 -97.8%
H
1.2
83.6
|
L
 -100.0%
H
1.2
17344.8
|
L
H
1.2
1424940
|
| Nurix Therapeutics Inc |
|
1,726.9
|
16.7
|
L
 -1.6%
H
16.5
17.1
|
L
 7.1%
H
15.5
17.1
|
L
 11.0%
H
14.0
17.2
|
L
 -11.5%
H
14.0
20.2
|
L
 70.1%
H
8.2
22.5
|
L
 36.7%
H
4.2
29.6
|
L
 -46.1%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
24.0
|
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
H
0.7
0.8
|
L
 -16.3%
H
0.6
1.1
|
L
 -27.3%
H
0.6
1.1
|
L
 -32.1%
H
0.6
2.6
|
L
 -55.8%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
83.3
|
2.5
|
L
H
2.4
2.6
|
L
 12%
H
2.2
2.6
|
L
 35.5%
H
1.7
2.6
|
L
 17.2%
H
1.6
2.6
|
L
 27.9%
H
1.6
3.8
|
L
 -59.3%
H
1.1
54
|
L
 -99.2%
H
1.1
488
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,666.9
|
14.1
|
L
 -5.6%
H
13.9
15.0
|
L
 1.7%
H
13.3
15.3
|
L
 10.6%
H
11.6
15.3
|
L
 18.9%
H
10.9
17.1
|
L
 91.7%
H
6.7
28.3
|
L
 -63.0%
H
5.9
47.5
|
L
 -81.1%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
8,092.0
|
102.9
|
L
 -1.7%
H
101.8
104.5
|
L
 -2.0%
H
99.8
107.1
|
L
 5.1%
H
93.9
107.1
|
L
 -3.0%
H
93.9
113.0
|
L
 45.4%
H
63.6
113.0
|
L
 263.2%
H
28.7
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,411.0
|
8.7
|
L
 -0.4%
H
8.5
8.8
|
L
 2.9%
H
8.0
8.8
|
L
 -15.4%
H
7.6
10.9
|
L
 11.3%
H
7.6
12.0
|
L
 35.5%
H
5.8
12.0
|
L
 -5.5%
H
3.5
23.9
|
L
 -95.7%
H
3.5
277.8
|
L
 -92.1%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
220.7
|
8.3
|
L
 -2%
H
8.3
8.5
|
L
 2.3%
H
7.9
8.9
|
L
 -7.8%
H
7.2
9.3
|
L
 -2.3%
H
7.2
9.9
|
L
 -12.6%
H
5.6
11.5
|
L
 -43.5%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
39.7
|
11.2
|
L
 -11.4%
H
10.6
13.0
|
L
 -0.1%
H
10.6
13.5
|
L
 -12.1%
H
8.6
13.5
|
L
 -13.4%
H
8.6
14.7
|
L
 178.8%
H
3.7
15.7
|
L
 -38.1%
H
2.8
30.8
|
L
 -90.2%
H
2.8
122.8
|
L
H
2.8
1308
|
| NuCana PLC (ADR) |
|
8.9
|
2.1
|
L
 -1.8%
H
2.1
2.2
|
L
 12.6%
H
1.9
2.3
|
L
 12.0%
H
1.3
2.3
|
L
 -35.9%
H
1.3
3.5
|
L
 -100.0%
H
1.3
50000
|
L
 -100.0%
H
1.3
960000
|
L
 -100.0%
H
1.3
4620000
|
L
H
1.3
32000000
|
| Ocugen Inc |
|
632.8
|
1.9
|
L
 -1.0%
H
1.9
2.0
|
L
 3.8%
H
1.7
2.0
|
L
 -22.2%
H
1.7
2.7
|
L
 19.1%
H
1.3
2.7
|
L
 175.7%
H
0.6
2.7
|
L
 141.3%
H
0.3
2.7
|
L
 -68.6%
H
0.3
17.7
|
L
 -98.6%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,571.4
|
27.1
|
L
 -1.6%
H
27
27.9
|
L
 -0.9%
H
26.9
28.3
|
L
 6.6%
H
24.0
28.3
|
L
 13.7%
H
23.6
30.7
|
L
 51.1%
H
16
30.7
|
L
 185.3%
H
9.1
30.7
|
L
H
6.3
30.7
|
L
H
6.3
30.7
|
| Ocular Therapeutix Inc |
|
1,913.5
|
8.8
|
L
 -1.4%
H
8.7
8.9
|
L
 4.4%
H
8.3
9.4
|
L
 0.3%
H
7.4
9.4
|
L
 -22.1%
H
6.2
11.9
|
L
 16.7%
H
6.2
16.4
|
L
 67.1%
H
2
16.4
|
L
 -45.6%
H
2
19.8
|
L
 -29.4%
H
2
24.3
|
| Opus Genetics Inc |
|
405.5
|
5.7
|
L
 -0.2%
H
5.6
5.8
|
L
 10.7%
H
5.1
5.8
|
L
 13.3%
H
4.2
5.8
|
L
 174.0%
H
2.0
5.8
|
L
 612.5%
H
0.7
5.8
|
L
 6.3%
H
0.7
6.6
|
L
 22.3%
H
0.7
7
|
L
 -96.3%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
110.3
|
3.4
|
L
 0.3%
H
3.1
3.6
|
L
 13.6%
H
2.6
4.1
|
L
 -30.1%
H
2.4
5.0
|
L
 -48.2%
H
2.4
7.5
|
L
 16.7%
H
2.3
8.5
|
L
 -46.2%
H
1.9
8.5
|
L
 -96.6%
H
1.9
125
|
L
 -96.9%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
84.0
|
1.6
|
L
 -3.0%
H
1.6
1.7
|
L
 0.6%
H
1.5
1.7
|
L
 -3.6%
H
1.4
1.7
|
L
 -33.1%
H
1.4
2.5
|
L
 42.9%
H
1.1
3.4
|
L
 33.3%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
1,434.6
|
16.5
|
L
 -0.2%
H
16.2
16.7
|
L
 4.9%
H
15.6
17.0
|
L
 11.9%
H
13.1
17.0
|
L
 -43.6%
H
13.0
29.5
|
L
 291.0%
H
3.9
36.3
|
L
 349.7%
H
2.9
36.3
|
L
 -53.5%
H
2
36.7
|
L
H
2
60.3
|
| Omeros Corp |
|
899.2
|
12.5
|
L
 2.0%
H
12.1
12.6
|
L
 8.5%
H
11.3
12.6
|
L
 11.6%
H
9.8
13
|
L
 2.3%
H
9.8
13
|
L
 81.8%
H
3.0
17.7
|
L
 96.7%
H
0.9
17.7
|
L
 -32.2%
H
0.9
19.4
|
L
 -17.1%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
124.3
|
1.1
|
L
 -2.7%
H
1.1
1.1
|
L
 17.6%
H
0.9
1.1
|
L
 9.2%
H
0.8
1.1
|
L
 10.3%
H
0.8
1.3
|
L
 87.7%
H
0.3
1.5
|
L
 -7.0%
H
0.3
3.4
|
L
 -63.5%
H
0.3
3.4
|
L
 -73.4%
H
0.3
8.5
|
| Traws Pharma Inc |
|
9.7
|
1.2
|
L
 -0.8%
H
1.0
1.3
|
L
 -21.8%
H
1.0
1.7
|
L
 -39%
H
1.0
2.3
|
L
 -29.1%
H
1.0
3.0
|
L
 -42.7%
H
1.0
3.3
|
L
 -92.8%
H
1.0
36.3
|
L
 -99.5%
H
1.0
412.5
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
4.3
|
1.5
|
L
 -2.0%
H
1.5
1.6
|
L
 -6.3%
H
1.4
1.6
|
L
 -17.8%
H
1.3
1.9
|
L
 -26.4%
H
1.3
3.4
|
L
 -10.8%
H
1.3
5.3
|
L
 -94.2%
H
0.3
26.9
|
L
 -98.6%
H
0.3
135
|
L
 -99.8%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
1,158.2
|
10.3
|
L
 0.6%
H
10.1
10.5
|
L
 14.3%
H
8.9
10.9
|
L
 -13.1%
H
7.2
13.0
|
L
 -10.2%
H
7.2
14.3
|
L
 105.2%
H
4.5
14.9
|
L
 71.2%
H
3.9
16.7
|
L
 -52.8%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
156.5
|
3.9
|
L
 1.3%
H
3.8
3.9
|
L
 11.2%
H
3.4
3.9
|
L
 12.8%
H
3.2
3.9
|
L
 12.5%
H
3.1
3.9
|
L
 73.5%
H
2.0
3.9
|
L
 72.8%
H
1.7
5.3
|
L
 -55.9%
H
1.7
31.5
|
L
 -58.4%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
28.2
|
0.3
|
L
H
0.3
0.3
|
L
 8%
H
0.2
0.3
|
L
 -30.8%
H
0.2
0.4
|
L
 -48.1%
H
0.2
0.6
|
L
 -80.6%
H
0.2
3.0
|
L
 -99.9%
H
0.2
812
|
L
 -100.0%
H
0.2
1308
|
L
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
421.4
|
2.8
|
L
 1.1%
H
2.8
2.9
|
L
 7.3%
H
2.7
3.1
|
L
 41.6%
H
1.9
3.1
|
L
 75.5%
H
1.4
3.1
|
L
 862.1%
H
0.3
3.1
|
L
 -10%
H
0.2
4.1
|
L
 -27.0%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
2,182.4
|
53.8
|
L
 -2.1%
H
53.5
55.6
|
L
 -8.2%
H
53.5
60.1
|
L
 8.8%
H
49.9
60.1
|
L
 34.4%
H
38.3
60.1
|
L
 220.3%
H
16.2
60.1
|
L
 243.1%
H
9.4
60.1
|
L
 118.0%
H
9.4
60.1
|
L
 121.2%
H
9.4
60.1
|
| Palisade Bio Inc |
|
387.2
|
2.3
|
L
 -1.3%
H
2.3
2.4
|
L
 23.5%
H
1.8
2.4
|
L
 19.1%
H
1.5
2.4
|
L
 32%
H
1.5
2.4
|
L
 239.7%
H
0.5
2.6
|
L
 -91.9%
H
0.4
36.6
|
L
 -100.0%
H
0.4
8460
|
L
 -100.0%
H
0.4
924300
|
| Passage Bio Inc |
|
38.4
|
12.0
|
L
 0.6%
H
10.9
12
|
L
 28.7%
H
9.0
12
|
L
 60.5%
H
5.9
12
|
L
 -16.3%
H
5.9
14.8
|
L
 62.1%
H
5.1
20
|
L
 -44.1%
H
5.1
35.8
|
L
 -96.5%
H
5.1
396.8
|
L
H
5.1
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
1.7
|
1.6
|
L
 -4.7%
H
1.6
1.7
|
L
 -13.4%
H
1.6
2.1
|
L
 -91.7%
H
1.6
16.3
|
L
 -93.3%
H
1.6
28.4
|
L
 -99.9%
H
1.6
1680
|
L
 -100.0%
H
1.6
6036
|
L
 -100.0%
H
1.6
44642.4
|
L
H
1.6
146400
|
| Puma biotech Inc |
|
369.4
|
7.3
|
L
 -2.9%
H
7.2
7.6
|
L
 -3.3%
H
7.2
7.9
|
L
 23.1%
H
6.0
7.9
|
L
 13.8%
H
5.5
7.9
|
L
 145.3%
H
2.8
7.9
|
L
 140.4%
H
2.1
7.9
|
L
 -28.9%
H
1.6
12.0
|
L
 -77.2%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
964.9
|
23.8
|
L
 1.7%
H
23.2
23.8
|
L
 2.5%
H
23.0
24.4
|
L
 2.5%
H
21.2
24.4
|
L
 15.4%
H
18.8
24.4
|
L
 -4.2%
H
18.8
27.6
|
L
 -43.9%
H
11.2
48.6
|
L
 -64.1%
H
11.2
82.2
|
L
 -63.1%
H
11.2
82.2
|
| Processa Pharma Inc |
|
8.2
|
3.1
|
L
 4.7%
H
2.8
3.2
|
L
 2.7%
H
2.7
3.2
|
L
 5.1%
H
2.1
3.3
|
L
 -16.4%
H
1.8
3.7
|
L
 -54.1%
H
1.8
19.6
|
L
 -98.8%
H
1.8
450
|
L
 -99.9%
H
1.8
4635
|
L
 -100.0%
H
1.8
17937.5
|
| Vaxcyte Inc |
|
8,951.8
|
62.2
|
L
 2.9%
H
60
62.9
|
L
 3.5%
H
59.0
63.3
|
L
 14.0%
H
52.7
63.3
|
L
 29.5%
H
44.9
65
|
L
 105.8%
H
28.1
65
|
L
 70.4%
H
27.7
121.1
|
L
 219.1%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
69.8
|
1.3
|
L
 -8.1%
H
1.1
1.4
|
L
 26.3%
H
1.0
1.4
|
L
 98.4%
H
0.5
1.4
|
L
 33.0%
H
0.5
1.4
|
L
 12.6%
H
0.5
1.9
|
L
 -81.9%
H
0.5
10.3
|
L
 -76.0%
H
0.5
17.9
|
L
 -99.3%
H
0.5
355.4
|
| PepGen Inc |
|
115.4
|
1.7
|
L
 -2.9%
H
1.6
1.8
|
L
 0.6%
H
1.6
1.8
|
L
 -68.6%
H
1.3
5.5
|
L
 -66.5%
H
1.3
7.1
|
L
 27.5%
H
1.0
7.8
|
L
 -82.0%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,373.2
|
3.9
|
L
 -0.5%
H
3.8
3.9
|
L
 -5.8%
H
3.8
4.4
|
L
 10.5%
H
3.0
4.4
|
L
 -6.3%
H
3.0
5.5
|
L
 169.4%
H
1.2
5.5
|
L
 269.5%
H
0.7
5.5
|
L
 -50.4%
H
0.7
8.7
|
L
 -89.8%
H
0.7
38.5
|
| Phathom Pharma Inc |
|
996.8
|
12.6
|
L
 -1.9%
H
12.5
12.9
|
L
 6.3%
H
11.6
13.2
|
L
 21.0%
H
10
13.2
|
L
 -16.2%
H
10
15.0
|
L
 163.1%
H
2.2
18.3
|
L
 25.8%
H
2.2
19.7
|
L
 -66.1%
H
2.2
40.9
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
14.8
|
1.3
|
L
 -3.8%
H
1.3
1.3
|
L
 -2.3%
H
1.2
1.3
|
L
 8.6%
H
1.1
1.4
|
L
 12.4%
H
0.8
1.9
|
L
 -47.7%
H
0.8
4.2
|
L
 -97.2%
H
0.6
110.4
|
L
 -99.5%
H
0.6
307.8
|
L
 -100.0%
H
0.6
194238
|
| Pharvaris NV |
|
1,879.8
|
28.7
|
L
 -1.4%
H
28.2
29.1
|
L
 4.3%
H
26
29.2
|
L
 13.1%
H
25.0
29.9
|
L
 12.1%
H
24.5
29.9
|
L
 106.2%
H
13.4
29.9
|
L
 230.3%
H
7.9
33
|
L
 2.4%
H
1.8
33
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
80.5
|
1.3
|
L
 -0.8%
H
1.3
1.3
|
L
 -4.4%
H
1.3
1.4
|
L
 -3.7%
H
1.1
1.4
|
L
 1.6%
H
1.1
1.4
|
L
 -11.0%
H
1.1
2.0
|
L
 -95.1%
H
1.1
30.9
|
L
 -95.8%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
36.4
|
3.6
|
L
 4.6%
H
3.6
3.9
|
L
 7.7%
H
3.2
3.9
|
L
 6.8%
H
3.0
3.9
|
L
 18.7%
H
3
3.9
|
L
 -3.0%
H
2.8
7.1
|
L
 -50.3%
H
0.7
8.6
|
L
 -89.6%
H
0.7
40.5
|
L
 -97.4%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
7.9
|
0.7
|
L
 -2.6%
H
0.7
0.8
|
L
 8.8%
H
0.6
0.8
|
L
 7.3%
H
0.6
0.8
|
L
 -21.3%
H
0.6
1.1
|
L
 -41.7%
H
0.6
1.5
|
L
 -74.9%
H
0.6
3.2
|
L
 -97.0%
H
0.6
31.1
|
L
 -99.3%
H
0.6
253.4
|
| Praxis Precision Medicines Inc |
|
8,846.5
|
317.6
|
L
 -6.6%
H
314.1
340.4
|
L
 -0.8%
H
312.7
352.8
|
L
 8.1%
H
271.9
352.8
|
L
 6.7%
H
271.9
356
|
L
 970.6%
H
28.8
356
|
L
 2017.6%
H
12.5
356
|
L
 -18.1%
H
11.9
489
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
2.3
|
2.7
|
L
 1.1%
H
2.7
2.8
|
L
 16.2%
H
2.3
2.8
|
L
 -2.2%
H
1.8
2.9
|
L
 231.7%
H
0.6
3.7
|
L
 34.0%
H
0.6
3.7
|
L
 -92.5%
H
0.2
158.5
|
L
 -98.7%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
277.8
|
4.4
|
L
 -20.1%
H
4.2
5.5
|
L
 4.5%
H
3.8
5.5
|
L
 33.6%
H
2.8
5.5
|
L
 105.1%
H
1.8
5.5
|
L
 488%
H
0.7
5.5
|
L
 -45.7%
H
0.6
8.6
|
L
 -87.0%
H
0.6
45.3
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
662.6
|
3.7
|
L
 -3.2%
H
3.6
3.8
|
L
 3.7%
H
3.3
3.9
|
L
 0.6%
H
3.0
3.9
|
L
 -8.0%
H
3.0
4.8
|
L
 178.0%
H
1.1
6.9
|
L
 -72.6%
H
1.1
17.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
276.8
|
2.0
|
L
 -3.0%
H
1.9
2.0
|
L
 5.4%
H
1.8
2.0
|
L
 -13.3%
H
1.6
2.3
|
L
 -10.6%
H
1.6
2.6
|
L
 174.7%
H
0.5
7.1
|
L
 -84.1%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
204.4
|
1.9
|
L
 -2.5%
H
1.9
2.0
|
L
 6.0%
H
1.8
2.2
|
L
 6.6%
H
1.4
2.2
|
L
 22.8%
H
1.3
2.2
|
L
 63.0%
H
1.1
3.1
|
L
 -13.0%
H
1.1
4.6
|
L
 -68.6%
H
0.5
9.1
|
L
 -71.0%
H
0.5
24
|
| Prothena Corporation plc |
|
565.8
|
10.5
|
L
 -2.9%
H
10.5
10.9
|
L
 -1.3%
H
10.2
10.9
|
L
 14.1%
H
8.4
10.9
|
L
 13.5%
H
8.2
10.9
|
L
 9.6%
H
4.3
11.7
|
L
 -79.2%
H
4.3
79.7
|
L
 -59.0%
H
4.3
79.8
|
L
 -77.8%
H
4.3
79.8
|
| AlphaTON Cap Corp |
|
7.5
|
0.3
|
L
 -5.9%
H
0.3
0.3
|
L
H
0.3
0.4
|
L
 -15.8%
H
0.3
0.4
|
L
 -62.4%
H
0.3
1.0
|
L
 -96.0%
H
0.3
15.8
|
L
 -99.5%
H
0.3
88
|
L
 -99.9%
H
0.3
899.5
|
L
 -99.9%
H
0.2
1310
|
| Plus Therapeutics Inc |
|
40.8
|
6.0
|
L
 5.3%
H
5.5
6.0
|
L
 87.7%
H
3.1
6.1
|
L
 -4.8%
H
2.9
6.7
|
L
 -14.8%
H
2.9
8.7
|
L
 -63.5%
H
2.9
30.5
|
L
 -94.3%
H
2.9
127.5
|
L
 -99.2%
H
2.9
1327.5
|
L
 -100.0%
H
2.9
1012500
|
| PTC Therapeutics Inc |
|
5,944.1
|
71.8
|
L
 -2.4%
H
70.9
73.5
|
L
 0.8%
H
68.2
73.8
|
L
 11.4%
H
64
73.8
|
L
 -5.1%
H
61.4
78.4
|
L
 53.0%
H
36.0
87.5
|
L
 45.7%
H
17.5
87.5
|
L
 49.0%
H
17.5
87.5
|
L
 705.0%
H
4.0
87.5
|
| Protagonist Therapeutics Inc |
|
6,645.0
|
104.1
|
L
 -1.2%
H
102.5
104.5
|
L
 2.0%
H
95.4
106.7
|
L
 12.8%
H
90.6
107.8
|
L
 22.9%
H
77
107.8
|
L
 121.8%
H
41.3
107.8
|
L
 455.7%
H
13.7
107.8
|
L
 291.1%
H
6.9
107.8
|
L
H
4.5
107.8
|
| Pulmatrix Inc |
|
4.4
|
1.2
|
L
 -3.2%
H
1.2
1.3
|
L
 1.7%
H
1.2
1.3
|
L
 -42.7%
H
1.2
2.5
|
L
 -52.2%
H
1.2
3.4
|
L
 -77.6%
H
1.2
9.4
|
L
 -59.3%
H
1.2
10.4
|
L
 -93.5%
H
1.2
23.4
|
L
 -99.8%
H
1.2
1396
|
| Polypid Ltd |
|
88.4
|
4.6
|
L
 -1.9%
H
4.6
4.7
|
L
 9.5%
H
4.2
4.7
|
L
 10.5%
H
4.0
4.7
|
L
 5.5%
H
4.0
5.1
|
L
 71.5%
H
2.4
5.1
|
L
 -64.9%
H
2.3
14.1
|
L
 -98.4%
H
2.3
303
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
106.2
|
1.7
|
L
 -1.2%
H
1.7
1.7
|
L
 15.0%
H
1.4
1.8
|
L
 9.7%
H
1.3
1.8
|
L
 -8.2%
H
1.3
2
|
L
 83.7%
H
0.9
5.6
|
L
 -51.3%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
1,225.3
|
17.4
|
L
 -2.5%
H
17.1
17.7
|
L
 2.2%
H
16.8
18.4
|
L
 19.6%
H
14.7
18.4
|
L
 -4.5%
H
14.5
21.3
|
L
 112.6%
H
8.0
21.3
|
L
 51.7%
H
6.7
21.3
|
L
 27.8%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
3.8
|
4.1
|
L
 -0.2%
H
4.0
4.1
|
L
 -3.1%
H
3.9
4.3
|
L
H
3.6
4.4
|
L
 -36.9%
H
3.6
6.7
|
L
 -83.6%
H
3.6
29.4
|
L
 -99.9%
H
3.6
8640
|
L
 -100.0%
H
3.6
27000
|
L
 -100.0%
H
3.6
278000
|
| PureTech Health Plc ADR |
|
444.2
|
18.3
|
L
H
17.9
18.4
|
L
 16.2%
H
16.1
18.4
|
L
 9.7%
H
14.5
18.4
|
L
 -4.8%
H
14.5
19.9
|
L
 9.4%
H
14.5
19.9
|
L
 -33.6%
H
13.3
34
|
L
 -68.4%
H
13.3
59.9
|
L
H
13.3
65.9
|
| AIxCrypto Holdings Inc |
|
25.5
|
1.3
|
L
 1.6%
H
1.2
1.3
|
L
 -6.0%
H
1.2
1.4
|
L
 10.5%
H
1.1
1.5
|
L
 -46.6%
H
0.9
2.5
|
L
 -61.8%
H
0.9
8.8
|
L
 -97.3%
H
0.1
63
|
L
 -99.9%
H
0.1
1560
|
L
 -100.0%
H
0.1
468750
|
| Qilian Intl Holding Grp ltd (Class A) |
|
66.2
|
0.3
|
L
H
0.3
0.3
|
L
 13.8%
H
0.3
0.4
|
L
 -67.3%
H
0.3
1.1
|
L
 -90.6%
H
0.3
4.0
|
L
 -96.9%
H
0.3
17.2
|
L
 -94.5%
H
0.3
17.2
|
L
 -98.5%
H
0.3
25.0
|
L
H
0.3
110
|
| Quince Therapeutics Inc |
|
22.5
|
1.4
|
L
 12.2%
H
1.2
1.4
|
L
 -24.6%
H
1.1
1.6
|
L
 29.0%
H
0.8
3.8
|
L
 -95.2%
H
0.8
37.2
|
L
 -86.3%
H
0.8
45.5
|
L
 -91.0%
H
0.8
45.5
|
L
 -99.6%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
1,045.5
|
16.7
|
L
 -3.1%
H
16.2
17.2
|
L
 5.2%
H
13.2
18.2
|
L
 7.7%
H
13.2
18.2
|
L
 -23.9%
H
8.7
28.5
|
L
 73.3%
H
8.7
71.5
|
L
 -14.5%
H
3.7
71.5
|
L
 -52.9%
H
3.7
71.5
|
L
 28.3%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
11.5
|
6.4
|
L
 -1.4%
H
6.4
6.7
|
L
 6.8%
H
5.5
7.0
|
L
 -20.6%
H
5.5
10.8
|
L
 -40.0%
H
5.5
11.0
|
L
 9.0%
H
5.3
41.8
|
L
 -99.8%
H
5.1
8400
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Rain Oncology Inc |
|
84.8
|
2.3
|
L
 -7.9%
H
2.3
2.6
|
L
 -12.4%
H
2.0
2.7
|
L
 -20.5%
H
2.0
3.8
|
L
 -30.0%
H
2.0
3.8
|
L
 -3.3%
H
2.0
9.2
|
L
 -68.7%
H
0.8
10.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
89.7
|
0.9
|
L
 -6.3%
H
0.9
1.0
|
L
 8.4%
H
0.7
1.0
|
L
 -31.8%
H
0.7
1.4
|
L
 -35.3%
H
0.7
1.4
|
L
 -25.6%
H
0.4
3.9
|
L
 -82.8%
H
0.4
8.8
|
L
 -99.6%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Ultragenyx Pharmaceutical Inc |
|
2,409.8
|
24.5
|
L
 -2.7%
H
24.3
26.2
|
L
 5.9%
H
22.9
26.2
|
L
 14.9%
H
18.3
26.2
|
L
 4.3%
H
18.3
26.2
|
L
 -30.7%
H
18.3
42.4
|
L
 -35.8%
H
18.3
60.4
|
L
 -77.6%
H
18.3
119.5
|
L
 -65.4%
H
18.3
179.7
|
| Rocket Pharmaceuticals Inc |
|
424.5
|
3.9
|
L
 0.3%
H
3.8
3.9
|
L
 8.1%
H
3.5
3.9
|
L
 -17.8%
H
3.3
5.1
|
L
 4.9%
H
3
5.5
|
L
 -40.4%
H
2.2
8.3
|
L
 -78.2%
H
2.2
32.5
|
L
 -91.1%
H
2.2
49.7
|
L
 -89.4%
H
2.2
67.5
|
| Regeneron Pharma |
|
78,695.7
|
744.4
|
L
 -1.3%
H
742.7
756
|
L
 -4.0%
H
737.3
772.5
|
L
 -0.2%
H
727.9
781.2
|
L
 0.3%
H
718.4
815
|
L
 33.4%
H
476.5
821.1
|
L
 -10.2%
H
476.5
1211.2
|
L
 50.5%
H
476.5
1211.2
|
L
 83.0%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
182.5
|
2.2
|
L
 -3.1%
H
2.1
2.4
|
L
 -62.4%
H
1.5
6.7
|
L
 -69.1%
H
1.5
8.9
|
L
 -69.7%
H
1.5
9.1
|
L
 -71.3%
H
1.5
13.2
|
L
 -86.3%
H
1.5
24.8
|
L
 -92.9%
H
1.5
40.2
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.5
|
1.2
|
L
 -4.0%
H
1.2
1.3
|
L
H
1.1
1.3
|
L
 -4.0%
H
1.1
1.3
|
L
 -66.4%
H
1.1
5.8
|
L
 -96.7%
H
1.1
43.5
|
L
 -100.0%
H
1.1
9561.6
|
L
 -100.0%
H
1.1
2276064
|
L
H
1.1
2276064
|
| Regencell Bioscience Holdings Ltd |
|
14,844.6
|
30.0
|
L
 0.7%
H
29.4
30.5
|
L
 4.0%
H
27.8
33.5
|
L
 29.2%
H
22.3
40
|
L
 -0.1%
H
20
40
|
L
 3431.8%
H
0.7
83.6
|
L
 3956.8%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
7,126.6
|
126.4
|
L
 -4.2%
H
125.8
132.1
|
L
 5.5%
H
115.5
133.6
|
L
 10.7%
H
109.7
133.6
|
L
 -21.9%
H
109.7
174.9
|
L
 -0.2%
H
109.7
175.8
|
L
 -27.4%
H
103.0
211.1
|
L
 -40.8%
H
103.0
327.3
|
L
 351.1%
H
21.1
327.3
|
| Regenxbio Inc |
|
472.3
|
9.2
|
L
 -2.2%
H
9.0
9.4
|
L
 5.5%
H
8.4
9.6
|
L
 6.8%
H
7.6
9.6
|
L
 -33.5%
H
7.6
16.2
|
L
 39.7%
H
5.9
16.2
|
L
 -51.7%
H
5.0
28.8
|
L
 -74.5%
H
5.0
46.5
|
L
 -21.1%
H
5.0
85.1
|
| Rigel Pharma |
|
589.7
|
31.9
|
L
 -0.5%
H
31.3
32.3
|
L
 7.3%
H
28.8
32.3
|
L
 23.0%
H
25.0
32.3
|
L
 -15.5%
H
25.0
38.7
|
L
 87.3%
H
16.1
52.2
|
L
 2494.3%
H
0.7
52.2
|
L
 744.2%
H
0.6
52.2
|
L
 1132.0%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
2,872.1
|
16.1
|
L
 3.7%
H
15.2
16.5
|
L
 10.8%
H
14.2
16.5
|
L
 55.1%
H
9.3
16.5
|
L
 110.6%
H
7.0
16.5
|
L
 482.3%
H
2.5
16.5
|
L
 -7.9%
H
1.8
18.3
|
L
 -52.4%
H
1.8
38.6
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
727.9
|
6.9
|
L
 -3.3%
H
6.8
7.2
|
L
 -1%
H
6.8
7.9
|
L
 17.4%
H
5.7
7.9
|
L
 82.6%
H
3.2
7.9
|
L
 2138.7%
H
0.3
7.9
|
L
 156.1%
H
0.2
7.9
|
L
 -80.9%
H
0.2
40
|
L
 -50.4%
H
0.2
54
|
| TransCode Therapeutics Inc |
|
8.2
|
9.0
|
L
 0.9%
H
8.7
9.5
|
L
 7.5%
H
7.9
10.3
|
L
 -8.1%
H
7.9
10.3
|
L
 1.8%
H
7.9
12.6
|
L
 -19.3%
H
6.1
22.0
|
L
 -100.0%
H
6.1
328648.8
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| RenovoRx Inc |
|
44.6
|
1.0
|
L
 -2.9%
H
1.0
1.0
|
L
 5.3%
H
0.9
1.1
|
L
 17.9%
H
0.8
1.3
|
L
 -3.9%
H
0.8
1.3
|
L
 10%
H
0.7
1.5
|
L
 -64.6%
H
0.6
3.3
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
20,805.4
|
29.1
|
L
 -1.1%
H
29.0
29.7
|
L
 3.2%
H
27.9
29.7
|
L
 3.6%
H
26.0
29.7
|
L
 24.8%
H
21.0
30.3
|
L
 189.0%
H
9.9
30.3
|
L
 308.9%
H
7.6
30.3
|
L
 193.6%
H
2.5
30.3
|
L
H
2.5
30.3
|
| Royalty Pharma PLC (Class A) |
|
21,516.8
|
48.4
|
L
 -0.6%
H
48.2
49.0
|
L
 1.1%
H
47.4
49.0
|
L
 6.1%
H
44.7
49.1
|
L
 21.9%
H
38.9
49.1
|
L
 49.2%
H
31.6
49.1
|
L
 33.5%
H
24.1
49.1
|
L
 16.3%
H
24.1
49.1
|
L
H
24.1
56.5
|
| Revolution Medicines Inc |
|
29,399.0
|
148.4
|
L
 -2.8%
H
147.3
155.7
|
L
 53.3%
H
94.6
155.7
|
L
 56.4%
H
91.5
155.7
|
L
 20.4%
H
91.5
155.7
|
L
 308.5%
H
34
155.7
|
L
 570.1%
H
15.5
155.7
|
L
 279.5%
H
14.1
155.7
|
L
H
14.1
155.7
|
| Reviva Pharma Holdings Inc |
|
11.5
|
0.9
|
L
 2.3%
H
0.9
0.9
|
L
 13.9%
H
0.8
0.9
|
L
 -63.6%
H
0.6
2.7
|
L
 -87.1%
H
0.6
7.3
|
L
 -94.0%
H
0.6
23.2
|
L
 -99.1%
H
0.6
185
|
L
 -98.9%
H
0.6
190
|
L
H
0.6
302
|
| Recursion Pharma Inc (Class A) |
|
1,891.0
|
3.6
|
L
 -4.5%
H
3.5
3.9
|
L
 5.6%
H
3.2
3.9
|
L
 4.7%
H
2.8
3.9
|
L
 -22.8%
H
2.8
5.2
|
L
 -36.5%
H
2.8
7.2
|
L
 -39.7%
H
2.8
16.7
|
L
H
2.8
42.8
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
6,029.6
|
88.3
|
L
 0.6%
H
87.2
90.8
|
L
 3.3%
H
83.0
90.8
|
L
 1.1%
H
74.5
100
|
L
 -16.8%
H
74.5
111.3
|
L
 42.2%
H
55.3
122.2
|
L
 355.2%
H
15.5
122.2
|
L
 325.7%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
337.8
|
3.5
|
L
 -1.7%
H
3.5
3.6
|
L
 -0.8%
H
3.5
3.9
|
L
 35.8%
H
2.3
3.9
|
L
 25.6%
H
2.3
4.1
|
L
 34.7%
H
1.1
11.5
|
L
 101.7%
H
0.7
11.5
|
L
 -42.2%
H
0.7
17.4
|
L
 -93.4%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.2
|
0.8
|
L
 2.5%
H
0.8
0.9
|
L
 3.8%
H
0.8
0.9
|
L
 -4.6%
H
0.7
0.9
|
L
 -36.6%
H
0.7
1.4
|
L
 -61.2%
H
0.7
3.3
|
L
 -99.0%
H
0.7
90
|
L
 -100.0%
H
0.7
11180
|
L
 -100.0%
H
0.7
16540
|
| SAB Biotherapeutics Inc |
|
273.4
|
3.9
|
L
 -4.0%
H
3.9
4.1
|
L
 4.3%
H
3.7
4.1
|
L
 -6.3%
H
3.7
4.3
|
L
 -2.8%
H
3.5
5.2
|
L
 181.9%
H
1.3
6.6
|
L
 432.9%
H
0.4
6.6
|
L
 -60.9%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
923.4
|
3.5
|
L
 0.6%
H
3.4
3.5
|
L
 7.8%
H
3.1
4.1
|
L
 3.0%
H
2.7
4.1
|
L
 -25.9%
H
2.7
5.2
|
L
 103.5%
H
1.5
6.6
|
L
 -33.3%
H
1.3
12
|
L
 -85.9%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
85.0
|
1.8
|
L
 9.3%
H
1.6
1.8
|
L
 3.5%
H
1.5
1.8
|
L
 -11.6%
H
1.5
2.0
|
L
 -17.4%
H
1.5
2.5
|
L
 23.1%
H
1.4
5.0
|
L
 -92.5%
H
1.2
42.2
|
L
 -95.0%
H
1.2
146.2
|
L
 -89.5%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
4.9
|
1
|
L
H
1.0
1.0
|
L
 -4.8%
H
1.0
1.1
|
L
 -9.1%
H
1.0
1.2
|
L
 -18.0%
H
1.0
1.4
|
L
 -21.9%
H
1.0
2.4
|
L
 -98.5%
H
0.1
140
|
L
 -100.0%
H
0.1
6280
|
L
 -100.0%
H
0.1
224000
|
| Scilex Holding Co |
|
46.8
|
6.7
|
L
 5.7%
H
6.1
6.8
|
L
 -8.1%
H
4.2
7.4
|
L
 -19.6%
H
4.2
8.7
|
L
 -41.9%
H
4.2
12.3
|
L
 -3.8%
H
3.6
34.3
|
L
 -50.5%
H
0.2
34.3
|
L
 -33.1%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
46.9
|
1.1
|
L
 -5.4%
H
1.0
1.1
|
L
 5%
H
1.0
1.1
|
L
 22.1%
H
0.8
1.1
|
L
 64.1%
H
0.6
1.1
|
L
 14.1%
H
0.6
1.3
|
L
 -66.6%
H
0.6
3.9
|
L
 -86.5%
H
0.6
10.3
|
L
 -97.5%
H
0.6
55.1
|
| Seer Inc (Class A) |
|
115.1
|
2.0
|
L
 4.1%
H
1.9
2.1
|
L
 20.7%
H
1.7
2.1
|
L
 12.7%
H
1.7
2.1
|
L
 6.8%
H
1.7
2.2
|
L
 -2.9%
H
1.7
2.4
|
L
 -47.7%
H
1.5
5.7
|
L
 -96.1%
H
1.5
54.6
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
927.6
|
6.0
|
L
 -5.7%
H
6.0
6.5
|
L
 -2.6%
H
5.8
6.5
|
L
 -18.9%
H
5.6
8.0
|
L
 -18.6%
H
5.6
9.3
|
L
 -41.6%
H
5.6
15.6
|
L
 -41.6%
H
5.6
15.6
|
L
 -41.6%
H
5.6
15.6
|
L
 -41.6%
H
5.6
15.6
|
| Sangamo Therapeutics Inc |
|
111.9
|
0.3
|
L
 -3.6%
H
0.3
0.3
|
L
 3.9%
H
0.3
0.3
|
L
 -29.0%
H
0.2
0.4
|
L
 -37.2%
H
0.2
0.6
|
L
 -63.5%
H
0.2
0.8
|
L
 -83.6%
H
0.2
3.2
|
L
 -97.7%
H
0.2
12.8
|
L
 -96.1%
H
0.2
27.5
|
| Shuttle Pharma Holdings Inc |
|
5.7
|
1.0
|
L
 10.9%
H
0.9
1.2
|
L
 36%
H
0.7
1.2
|
L
 8.5%
H
0.5
1.2
|
L
 -31.1%
H
0.5
4.4
|
L
 -84.4%
H
0.5
11.3
|
L
 -99.6%
H
0.5
550
|
L
H
0.5
25252
|
L
H
0.5
25252
|
| SIGA Tech Inc |
|
331.0
|
4.6
|
L
 -1.7%
H
4.6
4.7
|
L
 0.9%
H
4.3
4.7
|
L
 -12.2%
H
4.3
5.5
|
L
 -30.1%
H
4.3
7.1
|
L
 -23.5%
H
4.3
9.6
|
L
 -22.4%
H
4.2
12.8
|
L
 -35.4%
H
4.2
27.0
|
L
 320%
H
0.6
27.0
|
| SILO Pharma Inc |
|
8.3
|
0.5
|
L
 24.4%
H
0.4
0.5
|
L
 15.9%
H
0.4
0.5
|
L
 59.4%
H
0.3
0.6
|
L
 34.2%
H
0.2
0.6
|
L
 -51.4%
H
0.2
1.2
|
L
 -78.5%
H
0.2
4.5
|
L
 -96.2%
H
0.2
496
|
L
 -99.0%
H
0.2
496
|
| Solid Biosciences Inc |
|
821.6
|
8.4
|
L
 0.4%
H
8.1
8.4
|
L
 4.1%
H
7.6
8.9
|
L
 14.2%
H
6.4
8.9
|
L
 47.5%
H
5.2
8.9
|
L
 209.3%
H
2.4
8.9
|
L
 64.7%
H
1.8
15.1
|
L
 -89.2%
H
1.8
81.9
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
245.1
|
75.5
|
L
 -5.3%
H
75
81
|
L
 1.4%
H
71.2
84.2
|
L
 -10.0%
H
61.9
93.5
|
L
 10.6%
H
48.3
98.0
|
L
 15008%
H
0.4
98.0
|
L
 1836.9%
H
0.3
98.0
|
L
 413.9%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Soleno Therapeutics Inc |
|
2,717.8
|
52.6
|
L
 0.0%
H
52.5
52.7
|
L
 -0.1%
H
52.4
52.7
|
L
 55.7%
H
29.4
52.7
|
L
 25.3%
H
29.4
52.7
|
L
 -25.2%
H
29.4
90.3
|
L
 1526.9%
H
3
90.3
|
L
 196.9%
H
0.9
90.3
|
L
 -40.6%
H
0.9
117.8
|
| SELLAS Life Sciences Grp Inc |
|
905.1
|
5.0
|
L
 2.7%
H
4.8
5.1
|
L
 3.7%
H
4.5
5.2
|
L
 -6.2%
H
4.0
5.7
|
L
 31.3%
H
3.5
6.1
|
L
 290.7%
H
1.3
6.1
|
L
 215%
H
0.5
6.1
|
L
 -36.1%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Summit Therapeutics Inc |
|
18,748.5
|
24.2
|
L
 14.5%
H
21.3
24.5
|
L
 28.6%
H
18.9
24.5
|
L
 50%
H
15.3
24.5
|
L
 40.0%
H
13.8
24.5
|
L
 -1.8%
H
13.8
36.9
|
L
 1440.1%
H
1.3
36.9
|
L
 331.8%
H
0.7
36.9
|
L
 245.9%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
2,094.8
|
23.8
|
L
 -2.4%
H
23.5
24.4
|
L
 -3.3%
H
23.5
25.2
|
L
 1.1%
H
22.4
25.6
|
L
 14.9%
H
19.2
25.6
|
L
 109.6%
H
8.6
25.6
|
L
 18.8%
H
8.6
25.6
|
L
 13.2%
H
8.6
29.9
|
L
 50.9%
H
3.4
29.9
|
| Soligenix Inc |
|
12.0
|
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -5.7%
H
1
1.3
|
L
 -13.4%
H
1
1.5
|
L
 -42%
H
1
6.2
|
L
 -95.4%
H
1
85.3
|
L
 -99.7%
H
1
384
|
L
 -99.9%
H
1
2160
|
| Sonoma Pharma Inc |
|
3.8
|
2.2
|
L
 -1.3%
H
2.2
2.3
|
L
 -3.5%
H
2.2
2.6
|
L
 -10.2%
H
2
2.6
|
L
 -32.4%
H
2
3.6
|
L
 -15%
H
2
6.9
|
L
 127.8%
H
0.1
6.9
|
L
 -72.4%
H
0.1
13.4
|
L
 -94.7%
H
0.1
74.2
|
| Synaptogenix Inc |
|
33.3
|
4.5
|
L
 -3.7%
H
4.2
4.6
|
L
 -14.2%
H
3.8
5.5
|
L
 -20.9%
H
3.8
7.2
|
L
 -17.9%
H
3.3
7.2
|
L
 104.6%
H
2.1
12.0
|
L
 418.6%
H
0.1
12.0
|
L
 -57.1%
H
0.1
14.5
|
L
H
0.1
14.5
|
| Sensei Biotherapeutics Inc |
|
40.9
|
30.6
|
L
 4.6%
H
28.8
30.6
|
L
 -3.7%
H
25.8
32.3
|
L
 -5.4%
H
23.0
36.1
|
L
 163.1%
H
8.4
36.8
|
L
 233.5%
H
5.3
36.8
|
L
 1.8%
H
5
38.8
|
L
 -89.8%
H
5
302.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
29.9
|
1.0
|
L
 2.1%
H
0.9
1.0
|
L
 12.9%
H
0.8
1.0
|
L
 3.2%
H
0.8
1
|
L
 -9.4%
H
0.8
1.2
|
L
 -73.8%
H
0.8
5.1
|
L
 -91.0%
H
0.8
16.9
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
91.5
|
66.7
|
L
 -3.8%
H
66.7
71.0
|
L
 4.7%
H
59.3
71.5
|
L
 11.0%
H
55.9
80
|
L
 -11.0%
H
48.1
87.4
|
L
 573.4%
H
4.3
240
|
L
 -54.2%
H
4.3
446.3
|
L
 -94.5%
H
4.3
1349.3
|
L
H
4.3
2670
|
| SciSparc Ltd |
|
2.3
|
4.1
|
L
 21.8%
H
3.4
4.6
|
L
 20.8%
H
3.0
4.6
|
L
 -5.3%
H
3.0
4.7
|
L
 -56.3%
H
3.0
10.5
|
L
 -92.4%
H
3.0
94.5
|
L
 -99.8%
H
3.0
4471.7
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| Spero Therapeutics Inc |
|
154.6
|
2.7
|
L
 1.1%
H
2.6
2.7
|
L
 -1.8%
H
2.6
2.9
|
L
 3.5%
H
2.2
2.9
|
L
 11.3%
H
2.1
2.9
|
L
 260.8%
H
0.6
3.2
|
L
 55.2%
H
0.5
3.2
|
L
 -80.0%
H
0.5
19.9
|
L
H
0.5
23.6
|
| ARS Pharma Inc |
|
802.3
|
8.1
|
L
 0.8%
H
7.9
8.2
|
L
 -1.3%
H
7.8
8.5
|
L
 -3.7%
H
7.2
9.1
|
L
 -27.1%
H
7.2
11.2
|
L
 -46.1%
H
6.7
18.9
|
L
 35.1%
H
2.6
18.9
|
L
 -79.3%
H
2.6
39.4
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
105.8
|
2.1
|
L
 -6.6%
H
1.9
2.3
|
L
 -33.0%
H
1.9
3.2
|
L
 -49.5%
H
1.9
4.6
|
L
 -8.7%
H
1.9
4.6
|
L
 -18.9%
H
1.2
5.3
|
L
 379.5%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
2,212.1
|
21.1
|
L
 -3.0%
H
20.8
22.0
|
L
 -3.8%
H
20.8
22.7
|
L
 28.5%
H
16.3
23.9
|
L
 -1.1%
H
15.5
24.7
|
L
 -61.3%
H
10.4
64.8
|
L
 -82.8%
H
10.4
173.3
|
L
 -71.0%
H
10.4
173.3
|
L
 -0.1%
H
8
181.8
|
| Scholar Rock Holding Corp |
|
5,708.5
|
49.7
|
L
 0.8%
H
48.9
50.1
|
L
 -0.6%
H
48.5
50.6
|
L
 24.2%
H
38.8
51.6
|
L
 6.8%
H
38.8
51.6
|
L
 64.4%
H
27.1
51.6
|
L
 520.3%
H
5.6
51.6
|
L
 60.8%
H
4.3
51.6
|
L
H
4.3
70
|